

Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation

<https://doi.org/10.1038/s41586-025-08915-1>

Received: 10 December 2023

Accepted: 18 March 2025

Published online: 16 April 2025

Open access

 Check for updates

Amir Hosseini^{1,12}, Abhinav Dhall^{2,12}, Nemo Ikonen³, Natalia Sikora¹, Sylvain Nguyen¹, Yuqi Shen⁴, Maria Luisa Jurgensen Amaral⁵, Alan Jiao¹, Felice Wallner¹, Philipp Sergeev³, Yuhua Lim¹, Yuanqin Yang¹, Binje Vick^{6,7}, Kimihito Cojin Kawabata⁸, Ari Melnick⁸, Paresh Vyas^{4,9}, Bing Ren⁵, Irmela Jeremias^{6,7,10}, Bethan Psaila^{1,4,9}, Caroline A. Heckman^{3,11}, M. Andrés Blanco^{11,12} & Yang Shi^{1,2,12}✉

Impaired differentiation is a hallmark of myeloid malignancies^{1,2}. Therapies that enable cells to circumvent the differentiation block, such as all-*trans* retinoic acid (ATRA) and arsenic trioxide (ATO), are by and large curative in acute promyelocytic leukaemia³, but whether ‘differentiation therapy’ is a generalizable therapeutic approach for acute myeloid leukaemia (AML) and beyond remains incompletely understood. Here we demonstrate that simultaneous inhibition of the histone demethylase LSD1 (LSD1i) and the WNT pathway antagonist GSK3 kinase⁴ (GSK3i) robustly promotes therapeutic differentiation of established AML cell lines and primary human AML cells, as well as reducing tumour burden and significantly extending survival in a patient-derived xenograft mouse model. Mechanistically, this combination promotes differentiation by activating genes in the type I interferon pathway via inducing expression of transcription factors such as IRF7 (LSD1i) and the co-activator β -catenin (GSK3i), and their selective co-occupancy at targets such as STAT1, which is necessary for combination-induced differentiation. Combination treatment also suppresses the canonical, pro-oncogenic WNT pathway and cell cycle genes. Analysis of datasets from patients with AML suggests a correlation between the combination-induced transcription signature and better prognosis, highlighting clinical potential of this strategy. Collectively, this combination strategy rewires transcriptional programs to suppress stemness and to promote differentiation, which may have important therapeutic implications for AML and WNT-driven cancers beyond AML.

AML is a devastating disease with approximately 44,000 new cases diagnosed each year in the USA and EU, and with a 5-year survival rate varying considerably with age of the patients and genetic characteristics of the disease¹. The standard of care includes intensive combination chemotherapy, which can be consolidated with allogeneic stem and immune cell transplant. For patients ineligible for this option, targeted inhibitors such as hypomethylating agents combined with the BCL-2 inhibitor venetoclax² are used for specific genetic subgroups. Nevertheless, the median survival is still only

8.5 months^{2,5–7}. Accordingly, there is an outstanding need for novel AML treatments.

Although genetically heterogeneous, AMLs are universally characterized by a prominent differentiation block that disrupts normal myeloid maturation and promotes leukaemia cell self-renewal^{2,3}. Although differentiation arrest is a manifestation of the clinical phenotype, it also represents an AML vulnerability that can be leveraged for therapeutic purposes. Unlike most chemotherapy, which eliminates blasts via cytotoxicity, differentiation therapy aims to derepress terminal myeloid

¹Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK. ²Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. ³Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland. ⁴Medical Research Council Weatherall Institute of Molecular Medicine (MRC WIMM), University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK.

⁵Cell and Molecular Medicine, University of California San Diego, La Jolla, CA, USA. ⁶Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Munich, German Research Center for Environmental Health, Munich, Germany. ⁷German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and University Hospital LMU Munich, Munich, Germany.

⁸Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA. ⁹Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. ¹⁰Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany. ¹¹Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA. ¹²These authors contributed equally: Amir Hosseini, Abhinav Dhall. ✉e-mail: caroline.heckman@helsinki.fi; ablanco@vet.upenn.edu; yang.shi@ludwig.ox.ac.uk

maturation programs that reduce the competitive clonal advantage of leukaemia cells³. A notable example is acute promyelocytic leukaemia (APL), an AML subtype resistant to standard cytotoxic therapies³. In APL, ATRA induces leukaemia cell differentiation⁸ and leads to temporary remission⁹. However, when combined with ATO, the treatment is often curative in 95% of cases by degrading the PML–RAR α fusion protein and eliminating leukaemia stem cells (LSCs)^{10–12}. This highlights the importance of pursuing combination therapies that promote terminal maturation while inhibiting self-renewal^{3,13}.

Developing differentiation therapy for non-APL AMLs to approach the level of success of APL treatment remains a major goal. In this regard, inhibition of chromatin regulators represents an emerging, promising approach to induce the maturation of AML cells. Inhibitors of menin and DOT1L can induce varying degrees of differentiation in MLL-rearranged AML, and IDH1/2 inhibitors also induce differentiation and are highly effective in IDH1/2-mutant AML^{14–16}. In addition, histone demethylases are potential targets for AML therapy due to their role in AML development and progression¹⁷. In particular, the histone H3K4me1/2 demethylase LSD1 (ref. 18), whose expression is elevated in AML, is crucial for LSC maintenance and proliferation¹⁹, and inhibition of LSD1 has been shown to induce AML differentiation^{19,20}. Consequently, inhibitors of LSD1 are being actively investigated in clinical trials for haematological malignancies, including AML²⁰. However, therapeutic efficacy with LSD1 inhibitors alone is limited due to associated toxicities (NCT02177812)^{21,22}.

To enhance the efficacy and to mitigate the toxicity issue of LSD1 inhibitors, we screened small molecules for synergistic activity with the LSD1 inhibitor GSK–LSD1 in inducing AML cell differentiation²³ (Extended Data Fig. 1a,b). Using a collection of bioactive molecules, we performed the screen in ER-HOXA9 cells, a mouse bone marrow model in which ER-HOXA9 blocks myeloid differentiation and features a lysozyme–GFP reporter to assess differentiation²⁴ (Extended Data Fig. 1a). Among the compounds screened, the GSK3 inhibitor LY2090314 induced maturation with the most synergy in combination with a low dose of GSK–LSD1 (Extended Data Fig. 1c). Validation experiments confirmed that 50 nM GSK–LSD1 combined with LY2090314 robustly enhanced the levels of lysozyme–GFP and of the differentiation-associated markers CD11b and Gr-1 over 5 days (Fig. 1a).

GSK3 mediates degradation of the transcriptional co-activator β -catenin (encoded by *CTNNB1*)⁴. Upon GSK3i, stabilized β -catenin translocates into the nucleus and typically complexes with the transcription factors TCF and LEF to activate WNT pathway targets²⁵. The WNT pathway is associated with self-renewal and oncogenesis²⁵. As GSK3 negatively regulates the WNT pathway, it has not been traditionally thought of as an oncogene. However, in some AML subtypes, GSK3 has been shown to have oncogenic functionality by positively regulating the cell cycle²⁶ and the HOXA9–MEIS1 transcriptional program²⁷. Its inhibition induces cell-cycle arrest and differentiation and has thus been studied as a potential cancer therapeutic target^{26–28}. Unlike GSK–LSD1, LY2090314 was well tolerated by patients with AML and had robust on-target activity (more than 450% increase in β -catenin levels)²⁹. However, single treatment with LY2090314 showed less than desirable clinical efficacy²⁹.

To further test the efficacy of the GSK–LSD1 and LY2090314 drug combination (hereafter referred to as ‘combo’) in differentiation induction, we used orthogonal, functional readouts of myeloid maturation and found that combo treatment synergistically arrested proliferation, eliminated self-renewal as determined by colony formation assays and markedly induced a monocytic differentiation GFP reporter (Fig. 1b and Extended Data Fig. 1d,e). Of note, combo-treated colonies that did form displayed a distinct, diffuse architecture, indicating maturation (Extended Data Fig. 1e). These findings suggest that the combo induces the functional and physiological myeloid differentiation program in ER-HOXA9 cells.

To assess whether human AML cell lines can undergo differentiation by the combo treatment, we examined a mutationally diverse panel of six cell lines. In all cases, the combo treatment synergistically reduced the half-maximal effective concentration (EC_{50}) of the LY2090314 dose–response curve, demonstrated strong synergy (Fig. 1c and Extended Data Fig. 2a) and robustly reduced colony formation ability (Fig. 1d). To investigate self-renewal further, we performed serial colony formation assays with drug washouts. Cells isolated from the first plating of drug-treated colonies were harvested, washed and seeded serially for two additional rounds of plating without drug treatment. If self-renewal is lost after the first seeding, its depletion should remain without continued drug treatment. Indeed, after drug washout, colony formation ability was continually and progressively exhausted over the second and third plating in combo-treated cells, but not in control or single-drug-treated cells (Fig. 1e). Finally, the combo treatment synergistically induced high levels of CD11b in all cell lines and produced visibly mature cells (Fig. 1f and Extended Data Fig. 2b–d).

To investigate the selectivity of the combo treatment for leukaemia cells, we performed dose–response proliferation assays in mouse leukaemia cells and normal bone marrow-derived macrophages. Although RN2 (MLL-AF9/*Nras*^{G12V}) and HOXA9–MEIS1-overexpressing AML cells showed high sensitivity to the combo treatment, bone marrow-derived macrophage proliferation was unaffected even at the highest doses (Fig. 2a). Similarly, the combo treatment had no significant effect on the clonogenic activity and differentiation of normal mouse haematopoietic stem and progenitor-enriched Lin[−]Sca⁺Kit⁺ (LSK) populations (Fig. 2b,c). This suggests that the drug combo treatment has selectivity for leukaemic blasts and may be well tolerated in vivo.

As there are multiple inhibitors of LSD1 and GSK3, we next sought to confirm that the efficacy of combo treatment was not unique to GSK–LSD1 and LY2090314. We first tested bome demstat (IMG-7289), an irreversible LSD1 inhibitor in clinical trials for myeloid malignancies³⁰, and TAK-418 (ref. 31). Like GSK–LSD1, bome demstat or TAK-418 synergistically reduced proliferation and induced CD11b in combination with LY2090314 in THP-1 cells (Extended Data Fig. 2e–h). Although GSK–LSD1 has been shown to function mainly by disrupting the important LSD1–GFI1 interaction^{32–34}, TAK-418 mainly inhibits LSD1 demethylase activity with minimal disruption of the LSD1–GFI1 interaction³¹. Thus, these data suggest that disrupting the LSD1–GFI1 interaction or inhibiting LSD1 catalytic activity can both synergize with GSK3i to induce AML cell differentiation. We next tested the efficacy of another GSK3 inhibitor, 9-ING-41, which is also currently in clinical trials (NCT03678883)³⁵. As with LY2090314, a low dose of 9-ING-41 synergized with IMG-7289 to halt proliferation, clonogenic activity and markedly induce CD11b (Fig. 2d–f).

We next performed in vivo studies. We used a syngeneic HOXA9–MEIS1 retroviral overexpression transplant model that recapitulates much of MLL-AF9 AML biology while retaining applicability to non-MLL-rearranged AML types with prominent HOXA9 and MEIS1 activity²⁴. Although GSK–LSD1 and LY2090314 alone had a modest effect on disease progression and survival, the combo treatment provided the greatest reduction of disease progression (Fig. 2g) and yielded a significant lifespan extension (Fig. 2h).

Next, we wanted to explore what the molecular mechanism underlying the synergistic effect of the combo treatment to induce AML cell differentiation is. To address this, we first investigated the effects of drug treatment on the transcriptome and epigenome in ER-HOXA9 cells. As expected, after 5 days of treatment, more genes were differentially expressed in response to the combo treatment ($n = 2,201$) than to each drug alone ($n = 772$ for GSK–LSD1 and $n = 1,224$ for LY2090314; Supplementary Table 1). Principle component analysis (PCA) suggests that the combo treatment induced a chromatin state that is distant and distinct from the disparate states induced by single-agent treatment (Fig. 3a). Gene set enrichment analysis (GSEA) and clustering confirmed that the combo treatment synergistically upregulated myeloid differentiation




Fig. 1 | Combination of GSK-LSD1 and LY2090314 inhibits proliferation and impairs clonogenic activity of AML cell lines by inducing differentiation.

a, Time course measurement of monocyte differentiation markers in the ER-HOXA9 cell line treated with vehicle, GSK-LSD1 (50 nM), LY2090314 (100 nM) and a combination of both inhibitors for 5 days. Data are presented as mean $\pm$ s.d. from three biological independent experiments. P values were determined using two-way analysis of variance (ANOVA). CTRL, control. **b**, Time course measurement of ER-HOXA9 cell proliferation as in panel a. Data are presented as mean $\pm$ s.d. from three biological independent experiments. P values were determined using two-way ANOVA. **c**, Survival of human AML cell lines treated with different concentrations of LY2090314 (black) and a combination of LY2090314 with 50 nM GSK-LSD1 (red) for 3 days. The luminescence signal was

normalized, and dose-response curves and EC_{50} values were calculated using a non-linear regression curve fit. **d**, Quantification of colonies formed by the indicated human cell lines treated with DMSO, GSK-LSD1 (50 nM), LY2090314 (100 nM) and a combination of both inhibitors. Data are presented as mean $\pm$ s.d. from three biological independent experiments. P values were determined using two-way ANOVA. **e**, Analysis of the clonogenic activity of THP-1 cells by a serial replating assay. Data are presented as mean $\pm$ s.d. from three biological independent experiments. P values were determined using two-way ANOVA. **f**, Representative images of Kasumi-1, THP-1 and U937 cells treated with the indicated inhibitors for 5 days and stained with Wright-Giemsa. Scale bars, 25 μ m. The experiment was repeated three times with similar results.




Fig. 2 | Combo treatment specifically inhibits proliferation of leukaemia cells in vitro and in vivo. **a**, Mouse AML cells treated with 50 nM GSK-LSD1 and different concentrations of LY2090314 for 5 days; cell growth was determined by the Cell-Titer-Glo assay. Data are presented as mean $\pm$ s.d. from two biological independent experiments. BMDM, bone marrow-derived macrophage; RLU, relative light unit. **b**, Quantification of colonies formed by normal mouse LSK cells treated with the indicated inhibitors. Data are presented as mean $\pm$ s.d. from three biological independent experiments. *P* values were determined using two-way ANOVA. NS, not significant. **c**, Flow-cytometric quantification of CD11b and Gr-1 expression in the cells harvested from methylcellulose in panel **b**. **d**, Analysis of cell viability in THP-1 cells treated with the indicated inhibitors for 5 days by the Cell-Titer-Glo assay. Data are presented as mean $\pm$ s.d. from three biological independent experiments. *P* values were determined using two-way

ANOVA. **e**, Analysis of *CD11b* mRNA relative level in THP-1 cells treated with the indicated inhibitors for 5 days. Values were normalized against *GAPDH*. Data are presented as mean $\pm$ s.d. from three biological independent experiments. *P* values were determined using two-way ANOVA. **f**, Quantification of colonies formed by THP-1 cells treated with the indicated inhibitors. Data are presented as mean $\pm$ s.d. from three biological independent experiments. *P* values were determined using two-way ANOVA. **g, h**, Tumour burden (**g**) and Kaplan-Meier survival curves (**h**) of mice treated with vehicle ($n = 15$), GSK-LSD1 ($n = 9$), LY2090314 ($n = 11$) or a combination of both inhibitors ($n = 20$) in a syngeneic model of a HOXA9-MEIS1-driven AML model. *P* values were determined using the log-rank test. The error bars represent mean $\pm$ s.e.m. (**g**). *P* values were determined using two-way ANOVA.

expression signatures and downregulated LSC signatures (Fig. 3b–d and Extended Data Fig. 3a). These findings were also found in THP-1 cells (Extended Data Fig. 3b–e and Supplementary Table 2). Although LY2090314 demonstrated its on-target inhibitory effect, evidenced by reduced GSK3 α/β autophosphorylation on Tyr279/216 and the subsequent elevation of β -catenin levels^{36,37} (Extended Data Fig. 3f), canonical WNT pathway signatures were weakly, if at all, enriched in LY2090314 or combo-treated ER-HOXA9 and THP-1 cells (Extended Data Fig. 3g, h, and data not shown). In addition, TCF1, a key transcription factor that interacts with β -catenin to activate canonical WNT pathway target genes, was downregulated upon combo treatment (Extended Data

Fig. 3i). Collectively, these results provide compelling evidence that the combo treatment induces the differentiation program and impairs LSC activity, potentially by suppressing the WNT pathway.

We next focused on genes upregulated upon combo treatment. Enrichment analyses and manual inspection revealed a marked overrepresentation of genes in the type I interferon (IFN) signalling pathway, including *Stat1*, *Irf9*, *Irf7* and a panel of IFN-stimulated genes (ISGs) such as *Mx1*, *Ddx58* and *Oasl1*, which we termed the ‘synergy signature’ (Fig. 3e–g and Supplementary Table 3). These results were also found in THP-1 cells (Extended Data Fig. 3j–l). This suggests the possibility that activation of genes in the type I IFN pathway could be promoting




Fig. 3 | Combo treatment triggers alterations in the transcriptional and chromatin accessibility profiles associated with myeloid differentiation and IFN response in ER-HOXA9 cells. **a**, PCA of RNA sequencing (RNA-seq) of ER-HOXA9 cells treated with vehicle (VEH), GSK-LSD1, LY2090314 (LY) and a combination of both inhibitors (COMBO). **b**, GSEA of myeloid maturation signatures in drug-treated ER-HOXA9 cells. NES, normalized enrichment score. **c**, GSEA of additional myeloid maturation signatures in ER-HOXA9 cells treated with combo versus vehicle. **d**, Expression of genes relating to myeloid differentiation in drug-treated ER-HOXA9 cells. Data are presented as mean $\pm$ s.d. from three independent biological replicates. P values indicate the significance of unpaired, two-tailed Student's t -tests. See source data for individual P values. **e**, Heatmap of expression of genes synergistically upregulated or downregulated

upon combo treatment. **f**, Expression of genes relating to the type I IFN response in drug-treated ER-HOXA9 cells. Data are presented as mean $\pm$ s.d. from three independent biological replicates. See source data for individual P values. **g**, EnrichR database pathways enriched in upregulated combo synergy signature genes. Significance of enrichment z scores is shown as q values (corresponding to P values adjusted for significance by the Benjamini-Hochberg method). ChIP-seq, chromatin immunoprecipitation followed by sequencing; GO, Gene Ontology; TF, transcription factor. **h**, PCA of ATAC-seq in drug-treated ER-HOXA9 cells. **i**, ATAC-seq signal at promoters of type I IFN response genes in combo-treated and vehicle-treated ER-HOXA9 cells. **j**, Tracks showing ATAC-seq signal at the *Mx1* promoter in drug-treated cells. The asterisks indicate significance: * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$ and NS ($P > 0.05$).

combo-induced maturation, as IRF-family transcription factors can upregulate genes mediating the antimicrobial response component of functional granulocytic differentiation³⁸. We have recently demonstrated that LSD1i induces double-stranded RNA (dsRNA) and the IFN pathway in melanoma, which stimulates antitumour immunity³⁹. Similarly, we also observed elevated levels of dsRNA and *IFNB1* expression in AML cells treated with GSK-LSD1 alone or in combination with LY2090314 (Extended Data Fig. 3k,m). This suggests a conserved role of LSD1 in suppressing dsRNA and the IFN pathway across haematopoietic and select solid tumours and provides evidence of on-target effects of GSK-LSD1.

To determine the effect of the combo on the chromatin landscape, we performed ATAC-seq. We found that global levels of chromatin accessibility did not appear to change dramatically under any treatments, and PCA again showed that the combo treatment induced large chromatin-state changes distinct from single-agent treatment (Fig. 3h). Although motifs for differentiation-associated transcription factors such as ETS and ETV family factors were for the most part already enriched in open chromatin before drug treatments (Extended Data Fig. 3n and Supplementary Tables 4–6), significant increases in chromatin accessibility were observed at promoters of type I IFN pathway genes in the combo treatment compared with single-agent treatment (Fig. 3i,j). Of note, motifs for the WNT pathway transcription factors TCF and LEF were not strongly enriched in any treatments (Extended Data Fig. 3n). These findings are not unprecedented, as β -catenin can interact with transcription factors other than TCF1–LEF1, such as HIF1 α and IRF3 (refs. 40,41). For instance, in colorectal cancer cells exhibiting elevated hypoxia levels, the canonical β -catenin–TCF4 signalling pathway is redirected towards a β -catenin–HIF1 α signalling pathway⁴⁰. In addition, IRF3 and β -catenin interact and colocalize to the promoter region of *IFNB* in response to synthetic dsRNA⁴¹.

We hypothesized that β -catenin and IRF7 may form a critical regulatory unit that further drives the genes in the IFN pathway to induce differentiation upon combo treatment based on (1) the enrichment of type I IFN pathway regulatory elements in open chromatin, (2) the upregulation of IRF7, and (3) the stabilization of β -catenin in response to LY2090314 treatment. To test this hypothesis, we performed CUT&RUN on β -catenin and IRF7 in THP-1 cells. β -Catenin showed chromatin binding only in LY2090314 and combo-treated cells, as expected. IRF7 peaks, which are almost exclusively localized to promoters, were significantly higher in combo-treated cells than in single-agent-treated cells and were absent in control cells (Fig. 4a–c and Supplementary Tables 7, 8). β -Catenin and IRF7 also had higher binding signals at genes relating to the type I IFN pathway and myeloid differentiation upon combo treatment than upon single-agent treatment, consistent with combo-induced synergistic activation of genes in these pathways (Fig. 4d). In LY2090314-treated cells, IRF7 and β -catenin showed moderate colocalization, with 3,555 IRF7 peaks and 10,447 β -catenin peaks having 780 overlapping peaks (22% of IRF7 peaks and 8% of β -catenin peaks). However, combo treatment led to dramatically increased colocalization of β -catenin and IRF7, with 5,080 IRF7 peaks and 15,367 β -catenin peaks having 3,081 overlapping peaks (61% of IRF7 peaks and 20% of β -catenin peaks; Fig. 4c and Supplementary Table 9). Co-bound peaks localized primarily to promoters and were enriched for motifs of transcription factors that regulate myeloid differentiation such as PU.1, MYB and several ETS family factors (Fig. 4c,e and Supplementary Table 10).

Among the numerous changes detected in β -catenin and IRF7 localization upon drug treatments, the most notable was their co-occupancy at the promoters of several of the most critical drivers of the IFN response, such as *STAT1* and *STAT2*, upon combo, but not single-agent, treatment (Fig. 4f). This colocalization correlated with transcriptional outputs, as these genes were synergistically upregulated by combo treatment (Fig. 4f and Extended Data Fig. 4a–c). Consistently, in two additional AML cell lines, OCI-AML3 and MOLM-13, we observed strong

co-enrichment of both β -catenin and IRF7 on the promoters of key type I IFN genes – *STAT1*, *IFIH1* and *STAT2* – only in cells treated with combo (Extended Data Fig. 4d–g). Consistent with the function of LSD1 as an H3K4me1/2 demethylase¹⁸, inhibiting LSD1 resulted in a global increase in H3K4me1 levels, with this effect being more pronounced in combo-treated cells (Fig. 4b). This was associated with enhanced chromatin accessibility (Fig. 3h–j) and an increase in gene expression following combo treatment (Extended Data Fig. 4h).

Activation of STAT1, a critical transcription factor in the IFN pathway, has been linked to monocytic differentiation and the maturation of macrophages^{42–44}. This raises the possibility that the combo may promote differentiation by activating key IFN response and differentiation-promoting genes such as *STAT1*. To test this hypothesis, we first confirmed that the combo synergistically activated ISGs such as *ISG15* and *MX1* in all cell lines tested (Extended Data Fig. 4a–c). Combo treatment also synergistically upregulated the expression of *STAT1* transcripts, total STAT1 protein and activated phospho-STAT1 (Fig. 4f and Extended Data Fig. 5a). To determine the importance of STAT1 in mediating combo-induced differentiation, we treated THP-1 cells with single agents or the combo treatment and delivered the JAK1/JAK2 inhibitor ruxolitinib, which reduces the activated phospho-Y701 form of STAT1 (ref. 45) (Extended Data Fig. 5a). Ruxolitinib completely abrogated the induction of ISGs, indicating that combo-driven IFN pathway gene activation was dependent on STAT1 activation (Extended Data Fig. 5b). Ruxolitinib treatment also suppressed the combo-induced synergistic upregulation of CD11b, cell differentiation and losses of proliferation (Extended Data Fig. 5c–e). Similar results were also observed in MOLM-13 cells (Extended Data Fig. 5f–h).

To confirm that this was not due to off-target effects of ruxolitinib, we also genetically knocked out *STAT1* by CRISPR and found that *STAT1* knockout phenocopied all aspects of ruxolitinib treatment (Extended Data Fig. 5i–l). Finally, epigenomic co-occupancy data suggest that IRF7 and β -catenin may physically interact to coordinate transcriptional regulation at promoters of key regulators such as STAT1 (Fig. 4f). Consistently, co-immunoprecipitation experiments showed physical interactions between β -catenin and IRF7 only upon combo treatment (Extended Data Fig. 5m). Collectively, these data support our model that the combo treatment not only enhances the expression of type I IFN genes but also triggers the activation of IRF7 and stabilization of β -catenin, with their physical interaction and co-occupancy at promoters, particularly STAT1, leading to the activation of myeloid differentiation and stable and strong activation of the type I IFN pathway.

In addition to β -catenin localization to IFN pathway gene promoters, we also observed β -catenin and IRF7 colocalizing at promoters and occasionally gene bodies of cell-cycle regulators, including the classical β -catenin transcriptional targets such as *MYC* (Extended Data Fig. 5n). Indeed, co-bound β -catenin and IRF7 CUT&RUN peaks were enriched for G2/M checkpoint genes, MYC gene sets and E2F-binding motifs (Extended Data Fig. 5o,p and Supplementary Table 11). Cell-cycle and MYC-related genes with co-bound β -catenin and IRF7 were almost universally downregulated upon combo treatment, which is consistent with the functional effect of the combo treatment on reducing stemness and promoting differentiation, and further suggests that β -catenin and IRF7 could have context-specific transcriptionally repressive activity, contributing to suppressing oncogenesis.

The GSK3 gene family consists of two related kinases: GSK3 α and GSK3 β ^{36,37}. To determine whether the observed synergy is specific to GSK3 α , GSK3 β or both, we performed short hairpin RNA (shRNA) knockdowns (Extended Data Fig. 6a). Consistent with previous studies^{36,37}, knockdown of the gene encoding GSK3 β , but not the gene encoding GSK3 α , resulted in an increase in β -catenin levels, whereas depletion of GSK3 α led to moderate differentiation in AML cells^{36,46} (Extended Data Fig. 6a–d). Subsequently, we treated the GSK3 α -knockdown and GSK3 β -knockdown cells with inhibitors. GSK3 β knockdown did not affect cell proliferation or differentiation (Extended Data Fig. 6e–g),




Fig. 4 | Combo treatment induces selective co-occupancy of IRF7 and β-catenin at the promoter of the type I IFN signalling pathway genes. a, PCA of IRF7 and β-catenin CUT&RUN in THP-1 cells treated with vehicle, GSK-LSD1, LY2090314 and a combination of both inhibitors. **b**, Heatmaps showing global signal intensity of IRF7, β-catenin and H3K4me1 CUT&RUN in THP-1 cells treated with vehicle, GSK-LSD1, LY2090314 or a combination of both inhibitors. **c**, Venn diagrams showing overlap between IRF7 and β-catenin binding in LY2090314-treated and combo-treated THP-1 cells (top), and genomic distributions of singly and co-bound peaks shown for combo-treated cells (below). UTR, untranslated region. **d**, CUT&RUN signal of IRF7 and β-catenin at promoters of type I IFN

response genes (left two panels) and myeloid differentiation signature genes (right two panels) after drug treatments. TES, transcription end site; TSS, transcription start site. **e**, Enrichment of top motifs relating to myeloid differentiation in genomic regions co-bound by IRF7 and β-catenin. Motif enrichment significance was determined via hypergeometric tests. **f**, Tracks of IRF7, β-catenin and H3K4me1 CUT&RUN at the *STAT1* and *STAT2* loci in drug-treated THP-1 cells. Gene expression of each gene after drug treatments is shown to the right of the corresponding CUT&RUN track. Data are presented as mean ± s.d. from three independent biological replicates. *P* values indicate the significance of unpaired, two-tailed Student's *t*-tests.




Fig. 5 | See next page for caption.

but increased β -catenin levels (Extended Data Fig. 6e) and synergized with the LSD1i, which elevated IRF7 levels (Extended Data Fig. 6e–g). By contrast, although knockdown of the gene encoding GSK3 α led to moderate differentiation, it did not show any synergistic effects with

LSD1i (Extended Data Fig. 6h–k), probably because it did not increase the levels of the co-activator β -catenin (Extended Data Fig. 6h). In summary, the synergistic effects of GSK3i with LSD1i are primarily driven by GSK3 β i, which elevates the level of β -catenin, thus providing

Fig. 5 | Combo treatment promotes differentiation, reduces the clonogenic potential of human primary AML cells ex vivo and enhances survival in vivo.

a–c, Fold change induction of CD11b⁺ cells in primary AML samples ($n = 16$ biologically independent samples) cultured with varying concentrations of GSK-LSD1 (**a**) or LY2090314 (**b**) or a combination of both inhibitors (**c**) relative to the vehicle (dashed line). Each dot represents one primary sample. See the note for statistical analyses in the statistical analysis section in the Methods. **d–f**, Quantification of colonies formed by *DNMT3A*-mutant primary AML samples treated with the indicated inhibitors. Data are presented as mean $\pm$ s.d. from three biological independent experiments. *P* values were determined using two-way ANOVA. **g**, Quantification of colonies formed by normal haematopoietic progenitor cells treated with the indicated inhibitors. *P* values were determined using two-way ANOVA. Data are mean $\pm$ s.d. from six biologically independent

experiments. **h**, Kaplan–Meier survival curves of mice treated with vehicle ($n = 8$), GSK-LSD1 ($n = 8$), LY2090314 ($n = 8$) or a combination of both inhibitors ($n = 8$) in the OCI-AML3 model. *P* values were determined using the log-rank test. **P* = 0.0306 and ****P* = 0.0003. **i**, Kaplan–Meier survival curves of mice treated with vehicle ($n = 5$), GSK-LSD1 ($n = 5$), LY2090314 ($n = 5$) or a combination of both inhibitors ($n = 5$) in the *DNMT3A*-mutant AML-579 PDX model. *P* values were determined using the log-rank test. ***P* = 0.0025. **j**, Correlations between OHSU patient combo synergy enrichment scores, type I IFN response gene enrichment scores, WNT pathway gene enrichment scores and LSC signature gene enrichment scores in the OHSU patient cohort. *r* refers to the Pearson correlation coefficient. **k**, Kaplan–Meier plot showing overall survival of OHSU patients stratified by above and below the median combo synergy signature scores. *P* values were determined using the log-rank test.

a co-activator to work with key transcription factors (for example, IRF7) to regulate transcription networks that suppress stemness and promote differentiation. As GSK3 α i also modestly promotes differentiation, its inhibition by pan-GSK3i may also contribute to the overall effect of the combo treatment in inducing differentiation.

We next investigated the effect of combo on a cohort of primary samples from patients with AML cultured ex vivo. Among the 16 patient samples examined for their differentiation potential, 11 exhibited a more than fivefold increase in CD11b⁺ cells and responded more strongly to the combo treatment than to each inhibitor alone (Fig. 5a–c and Supplementary Table 12). *MLL* rearrangements and mutations in *DNMT3A* and *NPM1* were more frequently detected among the sensitive samples, consistent with previous findings that *MLL*-leukaemia are highly sensitive to LSD1¹⁹. Out of the 16 samples, 5 did not show a significant response. None had *DNMT3A* mutations. Collectively, these data raise the possibility that *DNMT3A* mutation may have an important role in the response to the combo treatment. In addition, two of these four non-responding patient samples had *TP53* mutations. AMLs with *TP53* mutation have previously been shown to be resistant to LSD1⁴⁷, which may contribute to their insensitivity to the combo treatment.

We further investigated the effect of the inhibitors on the clonogenic potential of an additional 12 primary samples from patients with AML, 7 of which had a *DNMT3A* mutation (Fig. 5d), whereas the other 5 were *DNMT3A* wild type (WT; Extended Data Fig. 7a–c). The combo treatment significantly suppressed the clonogenic potential of all *DNMT3A*-mutant samples, regardless of secondary mutations (Fig. 5d). In addition to *DNMT3A*, samples with an *NPM1* mutation also appeared to respond to the combo treatment (Extended Data Fig. 7a), whereas *DNMT3A*-WT and *TP53*-mutant samples appeared insensitive (Extended Data Fig. 7b,c). Combo-treated cells also had morphological characteristics of mature granulocytes (Extended Data Fig. 7d). Similar results were obtained using the combination of bome demstat and 9-ING-41 (Fig. 5e,f and Extended Data Fig. 7e). Similar to human AML cell lines, in these primary human AML samples, we also found that LY2090314 and combo treatment stabilized β -catenin, with the combo strongly upregulating ISG expression (Extended Data Fig. 7f,g). It has been shown that AML samples with a *DNMT3A* mutation exhibit elevated levels of endogenous retroelements and increased susceptibility to viral mimicry induced by azacytidine⁴⁸. We confirmed elevated expression of repetitive elements and ISGs in our *DNMT3A*-mutant AML samples (Extended Data Fig. 7h,i), suggesting that activity of an already elevated IFN pathway may sensitize the responsiveness of patient cells to further pathway activation induced by combo treatment. Consistent with the findings in AML cell lines, ruxolitinib also suppressed the effects of the combo treatment in primary cells (Extended Data Fig. 8a–h). Treatment with the inhibitors at the same concentrations had no effect on the colony formation and differentiation of normal human haematopoietic cells (Fig. 5g and Extended Data Fig. 8i,j). This suggests that the combo treatment selectively targets leukaemia cells with minimal effects on normal haematopoietic cells.

Next, we assessed the therapeutic potential of the combo treatment in in vivo models of an AML cell line and *DNMT3A*-mutated and *DNMT3A*-WT patient-derived xenografts (PDXs)^{49–51}. We first used the OCI-AML3 xenotransplantation model, which carries both *NPM1* and *DNMT3A* mutations and serves as an aggressive model of *DNMT3A*–*NPM1*-mutated AML, in which terminal disease develops within 3 weeks of transplantation⁴⁹. Vehicle-treated mice rapidly developed terminal leukaemia, with a median survival of 26 days (Fig. 5h). However, only the combo treatment significantly extended survival (Fig. 5h) and reduced splenomegaly (Extended Data Fig. 9a). We further evaluated the combo in a PDX model of *DNMT3A*-mutated leukaemia (AML-579)^{50,51}. Treatment began 13 days post-transplantation and continued for 2 weeks, during which no overt toxicity or body weight loss was observed (Extended Data Fig. 9b). In mice bearing AML-579, the combo treatment significantly reduced tumour burden, as measured by in vivo bioluminescence imaging (Extended Data Fig. 9c,d), and markedly increased survival, with three out of five mice achieving complete leukaemia clearance (Fig. 5i). By contrast, in a PDX model of *DNMT3A*-WT leukaemia (AML-372), although both LSD1i and the combo treatment led to a slight increase in survival and reduction in tumour burden, the combo treatment did not show any additional benefits over LSD1i alone (Extended Data Fig. 9e,f). Consistently, no significant toxicity or weight loss was observed in combo-treated mice (Extended Data Fig. 9g).

To validate the effectiveness of the combo treatment in promoting differentiation within a multicellular haematopoietic microenvironment, we used a three-dimensional model that more accurately mimics the human bone marrow tissue environment^{52,53}. The combo treatment significantly increased the population of CD11b⁺ cells compared with the DMSO-treated control and single-treatment conditions in the *DNMT3A*-mutant sample (Extended Data Fig. 9h). In the *DNMT3A*-WT sample, although the combo treatment led to a higher number of CD11b⁺ cells than the control, the single treatment, LY2090314, also resulted in a similar response (Extended Data Fig. 9h). In summary, results from multiple AML models demonstrate that the proposed combo treatment exhibits significant in vivo activity, evidenced by reduced leukaemia growth and prolonged survival in *DNMT3A*-mutated xenograft models. In *DNMT3A*-WT samples, although the combo treatment modestly increased survival and induced CD11b expression, its effect was not superior to that of single-agent treatment. Further research is warranted to investigate how we can enable patients with non-responsive, *DNMT3A*-WT respond to combo treatment, potentially by combining the combo treatment with hypomethylating agents^{54–56}.

Finally, we investigated whether our findings have clinical relevance by scoring patients of the OHSU dataset according to enrichment of the drug combo synergy signature, as well as signatures for LSCs, the type I IFN and WNT signalling. Consistent with predictions from our experimental studies, patient synergy signature scores positively correlated with the type I IFN pathway signature scores ($r = 0.62$; $P < 0.0001$) and strongly negatively correlated with the LSC signature ($r = -0.93$; $P < 0.0001$) and the WNT signalling pathway ($r = -0.42$; $P < 0.0001$) scores. As expected, the type I IFN pathway scores also negatively

correlated with the LSC signature scores ($r = -0.65$, $P < 0.0001$; Fig. 5j). As patients with *DNMT3A* mutation were most responsive to combo treatment, we also investigated the correlation between *DNMT3A* status and synergy scores in the OHSU cohort. Patients with *DNMT3A* mutation were significantly more likely to enrich the synergy signature than patients with *DNMT3A*-WT (Extended Data Fig. 10a,b). Finally, we investigated whether the synergy signature had prognostic value, reasoning that greater blast maturation would correspond to less-aggressive disease. Indeed, patients with above median synergy had significantly longer overall survival than patients with below median synergy (Fig. 5k).

The possibility that combo treatment may be actively suppressing the WNT pathway has profound ramifications for cancers beyond AML that are driven by canonical WNT signalling⁵⁷. However, interpretation of WNT pathway-related results in ER-HOXA9 and THP-1 cells is complicated by the fact that they have low endogenous WNT pathway activity (Extended Data Fig. 10c). To circumvent this, we generated a THP-1 line carrying a TCF/LEF reporter, which reports WNT activity⁵⁸. Although the reporter showed no detectable expression under basal condition, the addition of recombinant WNT3A strongly activated reporter expression, which was suppressed by the combo treatment (Extended Data Fig. 10c). To further determine whether the combo treatment can suppress WNT signalling, we used a WNT pathway-driven HCT116 colorectal cancer cell line carrying a TCF/LEF reporter. Combo treatment not only repressed the TCF reporter under basal condition but also actively suppressed recombinant WNT3A-induced WNT hyperactivation (Extended Data Fig. 10d). It will be of notable interest to determine whether this observation can be recapitulated in different WNT-driven oncogenic contexts in future experiments.

Discussion

Differentiation arrest is a hallmark of AML and represents a therapeutic vulnerability^{1,2}. Although differentiation therapy with ATRA/ATO is effective in APL³, its broader applicability in AML remains unclear. LSD1 inhibitors induce AML differentiation but have shown limited clinical success due to associate toxicity^{19,21,22}. Here we demonstrate that simultaneous LSD1i and GSK3i robustly promotes therapeutic differentiation of AML cells.

Although GSK3i has shown preclinical promise^{26,27,59}, its clinical utility is complicated by insufficient efficacy and by β -catenin stabilization and activation of WNT- β -catenin signalling, as this signalling pathway is crucial for maintaining the LSC population⁶⁰ and drug resistance⁶¹. Suppressing β -catenin delays disease progression in MLL-rearranged leukaemia⁶¹, but its role in primary AML varies⁶², suggesting subtype-specific effects. Furthermore, although GSK3 loss in haematopoietic progenitors has been linked to aggressive myelodysplasia and AML⁶³, recent studies have argued that these effects may stem from tamoxifen use in mouse models and GSK3 β i could be a viable therapeutic strategy^{64,65}. Further research is needed to fully understand how GSK3i alone affects AML and if there are AML subtypes that would respond more favourably to GSK3i. As GSK3i alone has not shown sufficient clinical efficacy²⁹, our findings are therefore important, as they suggest a new strategy that involves simultaneous GSK3i and LSD1i, which leads to therapeutically important maturation of AML cells while suppressing the WNT pathway. We also discovered the underlying molecular mechanism in which only the combo treatment induces expression and promotes co-occupancy of key transcription factors such as IRF7 and the co-activator β -catenin to drive transcription of genes in the type I IFN signalling pathway such as STAT1, which is critical for AML differentiation^{42–44}. STAT1, which we showed to be necessary for the combo treatment to induce differentiation, not only mediates an IFN response but also activates IFN-independent signalling^{66,67}. STAT1 has been reported to control the cell cycle by modulating the expression

of cyclin kinase inhibitors as well as various cyclins⁶⁸. In addition, STAT1 is important in inhibiting the expression of MYC⁶⁸. Therefore, the ability of STAT1 to activate IFN-independent signalling in addition to IFN response and cell-cycle regulation may also contribute to the overall differentiation response of AML cells.

As LSD1 and GSK3 inhibitors are both in clinical trials for a range of myeloid malignancies and advanced/metastatic cancer, respectively, their use as a combination therapy could conceivably enter the clinic in the near term. Finally, the unique ability of this combination strategy to suppress the canonical WNT pathway and re-route transcriptional programs to promote differentiation may also represent an unexplored therapeutic avenue of promise for numerous WNT-driven cancers.

Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41586-025-08915-1>.

- DiNardo, C. D., Erba, H. P., Freeman, S. D. & Wei, A. H. Acute myeloid leukaemia. *Lancet* **401**, 2073–2086 (2023).
- Döhner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. *Blood* **140**, 1345–1377 (2022).
- De Thé, H. Differentiation therapy revisited. *Nat. Rev. Cancer* **18**, 117–127 (2018).
- Liu, J. et al. Wnt/ β -catenin signalling: function, biological mechanisms, and therapeutic opportunities. *Signal Transduct. Target. Ther.* **7**, 3 (2022).
- Yi, M. et al. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. *J. Hematol. Oncol.* **13**, 72 (2020).
- Stahl, M. et al. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. *Blood Adv.* **2**, 923–932 (2018).
- Döhner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. *N. Engl. J. Med.* **373**, 1136–1152 (2015).
- Liu, T. X. et al. Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. *Blood* **96**, 1496–1504 (2000).
- Ablain, J. et al. Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies. *J. Exp. Med.* **210**, 647–653 (2013).
- Zhang, X. W. et al. Arsenic trioxide controls the fate of the PML-RAR α oncoprotein by directly binding PML. *Science* **328**, 240–243 (2010).
- Ablain, J. et al. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure. *Nat. Med.* **20**, 167–174 (2014).
- De Thé, H., Pandolfi, P. P. & Chen, Z. Acute promyelocytic leukemia: a paradigm for oncoprotein-targeted cure. *Cancer Cell* **32**, 552–560 (2017).
- McKenzie, M. D. et al. Interconversion between tumorigenic and differentiated states in acute myeloid leukemia. *Cell Stem Cell* **25**, 258–272.e9 (2019).
- Wang, F. et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. *Science* **340**, 622–626 (2013).
- Issa, G. C. et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. *Nature* **615**, 920–924 (2023).
- Dafflon, C. Complementary activities of DOT1L and menin inhibitors in MLL-rearranged leukemia. *Leukemia* **31**, 1269–1277 (2017).
- Højfeldt, J. W., Agger, K. & Helin, K. Histone lysine demethylases as targets for anticancer therapy. *Nat. Rev. Drug Discov.* **12**, 917–930 (2013).
- Shi, Y. et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. *Cell* **119**, 941–953 (2004).
- Harris, W. J. et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. *Cancer Cell* **21**, 473–487 (2012).
- Hosseini, A. & Minucci, S. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer. *Epigenomics* **9**, 1123–1142 (2017).
- Fang, Y., Liao, G. & Yu, B. LSD1/KDM1A inhibitors in clinical trials: advances and prospects. *J. Hematol. Oncol.* **12**, 129 (2019).
- Roboz, G. J. et al. Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. *Leuk. Lymphoma* **63**, 463–467 (2022).
- Zee, B. M. et al. Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia. *iScience* **24**, 102651 (2021).
- Sykes, D. B. et al. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. *Cell* **167**, 171–186.e15 (2016).
- Zhan, T., Rindtorff, N. & Boutros, M. Wnt signaling in cancer. *Oncogene* **36**, 1461–1473 (2017).
- Wang, Z. et al. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. *Nature* **455**, 1205–1209 (2008).
- Wang, Z. et al. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. *Cancer Cell* **17**, 597–608 (2010).
- McCubrey, J. A. et al. GSK-3 as potential target for therapeutic intervention in cancer. *Oncotarget* **5**, 2881–2911 (2014).

29. Rizzieri, D. A. et al. An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia. *Leuk. Lymphoma* **57**, 1800–1806 (2016).
30. Hiatt, J. B. et al. Inhibition of LSD1 with bomedemstat sensitizes small cell lung cancer to immune checkpoint blockade and T-cell killing. *Clin. Cancer Res.* **28**, 4551–4564 (2022).
31. Baba, R. et al. LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models. *Sci. Adv.* **7**, eaba1187 (2021).
32. Maiques-Diaz, A. Enhancer activation by pharmacologic displacement of LSD1 from GF11 induces differentiation in acute myeloid leukemia. *Cell Rep.* **22**, 3641–3659 (2018).
33. Hartung, E. E., Singh, K. & Berg, T. LSD1 inhibition modulates transcription factor networks in myeloid malignancies. *Front. Oncol.* **13**, 1149754 (2023).
34. Smitheman, K. N. et al. Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes. *Haematologica* **104**, 1156–1167 (2019).
35. Hsu, A. et al. Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 β (GSK-3 β) inhibitor, in refractory adult T-cell leukemia/lymphoma. *Cancer Biol Ther.* **23**, 417–423 (2022).
36. Banerji, V. et al. The intersection of genetic and chemical genomic screens identifies GSK-3 α as a target in human acute myeloid leukemia. *J. Clin. Invest.* **122**, 935–947 (2012).
37. Wagner, F. F. et al. Exploiting an Asp-Glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. *Sci. Transl. Med.* **10**, eaam8460 (2018).
38. Jefferies, C. A. Regulating IRFs in IFN driven disease. *Front. Immunol.* **10**, 325 (2019).
39. Sheng, W. et al. LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. *Cell* **174**, 549–563.e19 (2018).
40. Kaidi, A., Williams, A. C. & Paraskeva, C. Interaction between β -catenin and HIF-1 promotes cellular adaptation to hypoxia. *Nat. Cell Biol.* **9**, 210–217 (2007).
41. Yang, P. et al. The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a β -catenin-dependent pathway. *Nat. Immunol.* **11**, 487–494 (2010).
42. Kan, W. L. et al. Distinct assemblies of heterodimeric cytokine receptors govern stemness programs in leukemia. *Cancer Discov.* **13**, 1922–1947 (2023).
43. Coccia, E. M. et al. STAT1 activation during monocyte to macrophage maturation: role of adhesion molecules. *Int. Immunol.* **11**, 1075–1083 (1999).
44. Jerke, U. et al. Stat1 nuclear translocation by nucleolin upon monocyte differentiation. *PLoS ONE* **4**, e8302 (2009).
45. Ostojic, A., Vrhovac, R. & Verstovsek, S. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis. *Future Oncol.* **7**, 1035–1043 (2011).
46. Gupta, K. et al. GSK3 is a regulator of RAR-mediated differentiation. *Leukemia* **26**, 1277–1285 (2012).
47. Cai, S. F. et al. Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition. *Cancer Discov.* **10**, 1500–1513 (2020).
48. Scheller, M. et al. Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response. *Nat. Cancer* **2**, 527–544 (2021).
49. Liu, Y. et al. Small-molecule inhibition of the acyl-lysine reader ENL as a strategy against acute myeloid leukemia. *Cancer Discov.* **12**, 2684–2709 (2022).
50. Vick, B. et al. An advanced preclinical mouse model for acute myeloid leukemia using patients’ cells of various genetic subgroups and in vivo bioluminescence imaging. *PLoS ONE* **10**, e0120925 (2015).
51. Ebinger, S. et al. Plasticity in growth behavior of patients’ acute myeloid leukemia stem cells growing in mice. *Haematologica* **105**, 2855–2860 (2020).
52. Khan, A. K. et al. Human bone marrow organoids for disease modeling, discovery, and validation of therapeutic targets in hematologic malignancies. *Cancer Discov.* **13**, 364–385 (2023).
53. Olijnik, A. A. et al. Generating human bone marrow organoids for disease modeling and drug discovery. *Nat. Protoc.* **19**, 2117–2146 (2024).
54. Roulois, D. et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. *Cell* **162**, 961–973 (2015).
55. Mehdi-pour, P. et al. Epigenetic therapy induces transcription of inverted SINEs and ADAR1 dependency. *Nature* **588**, 169–173 (2020).
56. Hosseini, A. et al. Retroelement decay by the exonuclease XRN1 is a viral mimicry dependency in cancer. *Cell Rep.* **43**, 113684 (2024).
57. Zhang, Y. & Wang, X. Targeting the Wnt/ β -catenin signaling pathway in cancer. *J. Hematol. Oncol.* **13**, 165 (2020).
58. Tsuchiya, K. et al. Development of a penetratin-conjugated stapled peptide that inhibits Wnt/ β -catenin signaling. *Bioorg. Med. Chem.* **73**, 117021 (2022).
59. Holmes, T. et al. Glycogen synthase kinase-3 β inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth. *Stem Cells* **26**, 1288–1297 (2008).
60. Wang, Y. et al. The Wnt/ β -catenin pathway is required for the development of leukemia stem cells in AML. *Science* **327**, 1650–1653 (2010).
61. Yeung, J. et al. β -Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. *Cancer Cell* **18**, 606–618 (2010).
62. Gandillet, A. et al. Heterogeneous sensitivity of human acute myeloid leukemia to β -catenin down-modulation. *Leukemia* **25**, 770–780 (2011).
63. Guezguez, B. et al. GSK3 deficiencies in hematopoietic stem cells initiate pre-neoplastic state that is predictive of clinical outcomes of human acute leukemia. *Cancer Cell* **29**, 61–74 (2016).
64. Lee, G. et al. Loss of GSK3 β in hematopoietic stem cells results in normal hematopoiesis in mice. *Blood Adv.* **7**, 7185–7189 (2023).
65. Parameswaran, R. et al. Repression of GSK3 restores NK cell cytotoxicity in AML patients. *Nat. Commun.* **7**, 11154 (2016).
66. Nan, Y. et al. Interferon independent non-canonical STAT activation and virus induced inflammation. *Viruses* **10**, 196 (2018).
67. Cheon, H. & Stark, G. R. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. *Proc. Natl Acad. Sci. USA* **106**, 9373–9378 (2009).
68. Najjar, I. & Fagard, R. STAT1 and pathogens, not a friendly relationship. *Biochimie* **92**, 425–444 (2010).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2025

Methods

Small-molecule inhibitor screen

ER-HOXA9 cells were prepared in media with 50 nM GSK-LSD1 (Sellack Chemical) and seeded at a density of 50,000 cells per millilitre in 200 µl volume per well of a flat-bottom 96-well plastic plate (Genesee Scientific) using a Combi Reagent Dispenser (Thermo Fisher). Drugs in 100% DMSO (Sigma-Aldrich) were pin transferred (V&P Scientific) from 384-well stock plates into the 96-well plates containing our cells at approximately 300 nM drug stock per well. Cells treated with GSK-LSD1 alone served as negative control, whereas cells treated with GSK-LSD1 and 100 nM cytarabine (Sigma-Aldrich), a known synergistic combination, served as a positive control. Plates were incubated for 5 days and analysed on an iQue Screener Plus-VBR flow cytometer (Intellicyt) running the ForeCyt acquisition and analysis software (v9.0). Monocytic differentiation was assessed using an internal Lyz2-GFP marker (blue laser channel at 488-nm excitation and 530-nm emission). Viability was calculated by dividing the number of live cells by the number of total cells, and differentiation was calculated by dividing the number of Lyz2-GFP⁺ cells by the number of live cells.

Cell culture

ER-HOXA9 cells were grown in RPMI-1640 medium supplemented with 10% of fetal bovine serum (FBS), 100 ng ml⁻¹ stem cell factor (SCF; 78064, StemCell Technologies), 4 mM glutamine, 1% penicillin-streptomycin and 0.5 mM β-oestradiol (E2; E4389, Sigma-Aldrich). HOXA9-MEIS1 cells were similarly passaged as ER-HOXA9 cells except without E2. RN2 cells were cultured in RPMI-1640 medium supplemented with 10% FBS, 20 mM L-glutamine, 10 mM sodium pyruvate, 10 mM HEPES (pH 7.3), 1% penicillin-streptomycin and 50 µM β-mercaptoethanol.

THP-1 and U937 were grown in RPMI-1640 medium supplemented with 10% of FBS, 4 mM glutamine and 1% penicillin-streptomycin. MOLM-13 and Kasumi-1 were grown in RPMI-1640 medium supplemented with 20% of FBS, 4 mM glutamine and 1% penicillin-streptomycin. OCI-AML2 and OCI-AML3 were grown in α-MEM (with ribonucleosides and deoxyribonucleosides) with 20% FBS, 4 mM glutamine and 1% penicillin-streptomycin. Cells were maintained at 37 °C and 5% CO₂ with routine testing to confirm lack of mycoplasma infection.

Drug combination assay and synergy score analysis

The drug synergy assay was performed as previously described⁶⁹. In brief, cells were seeded into 96-well plates and exposed to various concentrations of inhibitors, both individually and in combination. Cell viability was quantified using Cell-Titer-Glo (Promega) and normalized to DMSO to calculate the inhibitory response. The resulting data were analysed using the SynergyFinder web application (<https://synergyfinder.fimm.fi>), which generated dose-response matrices for each drug combination. Synergy scores were calculated using the highest single-agent model to assess drug interactions. Heatmaps were generated to visualize the results, with the following interpretation thresholds: synergy scores below -10 indicated antagonism, scores between -10 and 10 suggested an additive effect, and scores above 10 indicated synergy.

Human primary AML samples

Bone marrow or peripheral blood samples were collected after informed consent from patients with AML using protocols approved by an Institutional Review Board at the Helsinki University Hospital (permit numbers 239/13/03/00/2010 and 303/13/03/01/2011) in compliance with the Declaration of Helsinki. Mononuclear cells were isolated from bone marrow or peripheral blood samples by Ficoll-Paque Premium (GE Healthcare) density gradient separation and viably frozen and stored in liquid nitrogen before further analyses.

LSK cell sorting and colony formation

Eight-week-old C57BL/6J mice were euthanized, and bone marrow was harvested from the femurs and tibias of both legs. Haematopoietic progenitor cells were enriched using the EasySep Mouse Haematopoietic Progenitor Cell Isolation Kit (19856, StemCell Technologies). Haematopoietic progenitor-enriched cells were then stained with antibodies to mouse KIT (clone: ACK2, 567818, BD Bioscience), Sca-1 (clone: E13-161.7, 753334, BD Bioscience), lineage markers (CD3, CD11b, CD19, B220, Gr1 and Ter119; 155606, 101212, 115512, 103212, 108412 and 116212, respectively, BioLegend), and Fixable Viability Stain 575V (565694, BD Bioscience). LSK cells were sorted using a FACS Aria Fusion (BD Bioscience). For the colony formation assay, 2,000 LSK cells were resuspended in 100 µl of IMDM and added to 1.5 ml of methylcellulose media (M3434, StemCell Technologies). Colonies were counted after 10 days of incubation at 37 °C. ImageJ (v1.54g) was used for the analysis of colonies morphology images.

Ex vivo drug sensitivity testing of primary AML cells

GSK-LSD1 and LY2090314 (MedChem Express) were dissolved in 100% DMSO and dispensed on Nunc 96-well polystyrene V-bottom plates (Thermo Fisher Scientific) using the Echo 550 Acoustic Dispenser (Labcyte) in seven different concentrations. GSK-LSD1 was plated in a concentration range of 1–250 nM and LY2090314 in a range of 50–500 nM as single agents and in combination. 0.1% DMSO was used as a negative control, and 100 µM benzethonium chloride (Sigma-Aldrich) was used as a positive control for total cell death.

Frozen mononuclear cells were thawed and suspended in 12.5% conditioned medium composed of RPMI-1640 medium (Corning) supplemented with 12.5% HS-5 cell-derived conditioned medium, 10% FBS, 2 mM L-glutamine and penicillin-streptomycin (100 U ml⁻¹)⁷⁰, and then treated with DENARASE (250 U µl⁻¹, c-LEcta) to degrade DNA released from dead cells; the cells were left to recover for 4 h in 12.5% conditioned medium. The cells were plated onto pre-drugged plates at a density of 50,000 cells per well and incubated with the drugs for 5 days (at 37 °C at 5% CO₂). After incubation, the cells were centrifuged (at 500g for 5 min) and resuspended in staining buffer (RPMI-1640, 10% FBS, 2 mM L-glutamine and 100 U ml⁻¹ penicillin-streptomycin). The cells were stained with antibodies to CD45-FITC (BD Pharmingen), CD34-APC (BD Pharmingen), CD15-PE-Cy7 (BioLegend), CD14-BV421 (BD Biosciences) and CD11b-BV605 (BD Horizon) for 30 min at room temperature in the dark. Subsequently, the cells were centrifuged (at 500g for 5 min) and excess antibodies were removed. The cells were resuspended and stained with PE annexin V and seven-amino actinomycin D in annexin V-binding buffer (BD Pharmingen) for 15 min at room temperature in the dark. The cells were analysed using the iQue Screener Plus-VBR flow cytometer, and gating was done with ForeCyt software (version 9.0, Intellicyt). Data were processed and analysed using R software (v4.2).

Seeding of organoids with primary patient samples and drug treatment

Human bone marrow organoids were generated from a fluorescent human induced pluripotent stem (iPS) cell line as previously described^{52,53}. The fluorescent iPS cell line, MCND-TENS2-mScarlet3, was obtained through CRISPR-Cas9-mediated knock-in of mScarlet3 at the AAVS1 safe harbour locus in the parental line MCND-TENS2 (registered at <https://hpscereg.eu/cell-line/RTIBDi001-A>), performed by the iPS Cell Core Facility at the US National Institutes of Health (NIH). On day 14 of organoid differentiation, individual mScarlet⁺ organoids were seeded into 96-well ultra-low attachment plates. Cryopreserved mononuclear cells from samples from patients with AML were then engrafted into the organoids at a density of 10,000 cells per organoid, with 8 organoids for each treatment condition. The organoids were subsequently cultured in StemPro-34 SFM medium (10639011,

Thermo Fisher Scientific) supplemented with 2% KnockOut serum (10828028, Thermo Fisher Scientific), 2% chemically defined lipids (I1905031, Thermo Fisher Scientific), 0.5% penicillin–streptomycin and cytokines (10 ng ml⁻¹ of SCF, FLT3-L, TPO, IL-6, G-CSF and GM-CSF, and 5 ng ml⁻¹ of IL-3). Twenty-four hours post-engraftment, the engrafted organoids were treated with either vehicle control, 25 nM GSK-LSD1, 50 nM LY2090314 or a combination of inhibitors for 5 days. Following treatment, the eight organoids from the same condition were pooled to minimize variations, and they were then dissociated using collagenase D (11088866001, Roche)⁷¹ and analysed by flow cytometry to determine the percentage of mScarlet⁺ CD11b⁺ cells.

Phosphoflow analysis

After thawing and DENARASE treatment as previously described, mononuclear cells from samples from patients with AML were plated onto pre-drugged Nunc 96-well V-bottom plate at a density of 200,000 cells per well and incubated with 50 nM GSK-LSD1, 100 nM LY2090314 and the combination of both drugs for 5 days (at 37 °C at 5% CO₂). After incubation with the drugs, the cells were washed with PBS, centrifuged (at 1,000g for 4 min) and stained with Zombie Yellow (BioLegend) viability marker for 30 min in the dark at room temperature. The cells were washed with staining buffer (5% FBS in Dulbecco's phosphate-buffered saline (DPBS)) and stained with surface markers for CD45–BV786 (BD Biosciences), CD38–BV421 (BD Biosciences), CD34–APC–Cy7 (BioLegend) and CD11b–BV605 (BD Horizon) for 30 min at room temperature. The cells were fixed in 1.5% paraformaldehyde solution in PBS pre-warmed to 37 °C for 15 min at room temperature. Fixed cells were centrifuged (at 1,000g for 4 min), washed with staining buffer and centrifuged again with the same settings. The cells were resuspended in ice-cold methanol and incubated at 4 °C for 30 min, after which the cells were washed twice with staining buffer with centrifugation (at 1,000g for 4 min). The cells were stained with β -catenin–AF488 (BD Pharmingen) for 1 h at room temperature. After incubation, the cells were washed with staining buffer, centrifuged (at 1,000g for 4 min), then resuspended and analysed on a iQue PLUS flow cytometer, and data were analysed using the Forecyt software (v9.0). Data were processed and analysed using R software (v4.2).

In vivo study

HXA9–MEIS1-overexpressing leukaemia cells previously developed by Sykes et al.²⁴ were virally transduced to express Luciferase and GFP for in vivo tracking. Cells expressing GFP were twice sorted and used to establish syngeneic mouse models of AML in 6–8-week-old female C57BL/6J mice purchased from Jackson Laboratory. Animals were maintained at Boston Children Hospital's ARCH facility and treated according to all protocols approved by the Institutional Animal Care and Use Committee under protocol number 16-09-3230R. The mice received sublethal radiation of 350 cGy 16–20 h before tail-vein injection of 0.5×10^4 leukaemia cells in 100 μ l PBS to establish a measurable residual disease model of AML. Leukaemia engraftment and therapy response were monitored using whole-body IVIS imaging through retro-orbital injection of luciferin. Mice were randomized into four treatment groups after engraftment was observed 7 days post-injection.

NSG (NOD.Cg-Prkdc^{SCID} Il2rgt^{m1WJ}/SzJ) mice were purchased from Charles River and irradiated with a sublethal dose of 1.5 Gy 24 h before intravenous injection. For the OCI-AML3 model, approximately 1 million cells were transplanted via tail-vein injection into 6–8-week-old male or female NSG recipient mice. To assess leukaemia development, peripheral blood was collected from the mice, stained for human CD45 and analysed by flow cytometry; treatment was initiated 13 days after transplantation, once hCD45⁺ cells were detected in the peripheral blood. For luciferase-expressing PDX samples, AML-372 (*DNMT3A*-WT) and AML-579 (*DNMT3A*-mutant) models^{50,51}, about 700,000 and 1 million cells, respectively, were transplanted via tail-vein injection into 6–8-week-old female NSG recipient mice and treatment was initiated

13 days after transplantation. Engraftment and leukaemia burden were evaluated using a bioluminescence imaging system following the intravenous administration of D-luciferin (P1043, Promega). For in vivo treatments, either GSK-LSD1 (0.25 mg kg⁻¹), LY2090314 (10 mg kg⁻¹) or a combination of both was administered via intraperitoneal injections every alternate day for 1 week (HXA9–MEIS1 model) or 2 weeks (OCI-AML3 model and PDX models). Animals were monitored daily, and body weights were measured throughout the treatment period. Mice exhibiting signs of distress, rough fur, hunchback and reduced motility were euthanized by a schedule 1 method. Kaplan–Meier survival curves were generated using GraphPad Prism (v10) software. All cages were on a 12-h–12-h light–dark cycle (lights on at 07:00) in a temperature-controlled and humidity-controlled room. Room temperature was maintained at 19–23 °C, and room humidity was maintained at 45–65%. All mouse procedures were carried out in accordance with UK Animals (Scientific Procedures) Act 1986 and University of Oxford Animal Welfare and Ethical Review Body approval under Project license (PPL) number PP4128654.

Dot blots

Purified total RNA from treated cells were subjected to digestion with mock, RNase T1 (AM2283, Thermo Fisher Scientific) and RNase III (AM2290, Thermo Fisher Scientific) in their respective buffers and according to the manufacturer's instructions, or RNase A (EN0531, Thermo Fisher Scientific) under high-salt condition (350 mM NaCl). The digestion was deactivated by the addition of TRIzol and RNA samples extracted using the TRIzol manufacturer's protocol (R2053, Zymo Research). Equal volumes (3 μ l) of purified RNA were dotted on Hybond N⁺ membrane (RPN119B, GE Healthcare), air dried for 10–15 min at room temperature, then UV crosslinked in a UV stratalinker 2400 (Stratagene) two times. The membrane was blocked for 1 h in blocking buffer (5% milk diluted in 0.01% PBS-T) and probed with J2 antibody (RNT-SCI-10010500, Jena Bioscience) rocking overnight at 4 °C. On the next day, the membrane was washed three times in PBS-T, rocking for 10 min at room temperature per wash and probed with secondary goat-anti-mouse horseradish peroxidase (HRP) antibody in 5% milk at room temperature for 1 h. Membrane was washed three times in PBS-T, rocking for 10 min at room temperature per wash, and enhanced chemiluminescence (ECL) was applied for chemiluminescent development. To detect total nucleic acid loading, the membrane was then incubated in 0.5% methylene blue in 30% EtOH to visualize the presence of RNA.

CRISPR–Cas9 gene knockouts

CRISPR gene editing was performed using the Integrated DNA Technologies (IDT) Alt-R CRISPR–Cas9 System as per the manufacturer's protocol. In brief, Alt-R CRISPR–Cas9 CRISPR RNA (crRNA) was mixed with Alt-R CRISPR–Cas9 trans-activating crRNA (tracrRNA) and Alt-R HiFi S.p. Cas9 Nuclease V3 to assemble the ribonucleoprotein complex. Subsequently, this complex was electroporated into target cells using the Neon transfection system, using a pulse voltage of 1,400, a width of 10 ms and three pulses. Alt-R CRISPR–Cas9 negative control crRNA #2 was used for the creation of non-targeted controls. Specific gene knockouts were generated using guide RNAs listed in Supplementary Table 13 that were selected using the IDT predesign and selection tool.

Gene knockdown by shRNA

Target sequences for shRNA knockdown of the genes encoding GSK3 α and GSK3 β were sourced from existing literature³⁶ and oligos were ordered from IDT. In brief, shRNA oligos were annealed and ligated into the pLKO.1-Puro (Addgene #10878) plasmid backbone (digested with AgeI and EcoRI) overnight and subsequently transformed into NEB stable-competent *Escherichia coli* (C3040H, NEB). Colonies were screened for correct insertion using primers flanking approximately 100 bp upstream and downstream of the AgeI and EcoRI restriction sites. Positive clones were isolated and sent for sequencing before

Article

co-transfection with pCMV-dR8.2 and pCMV-VSVG into HEK293T cells for lentivirus production.

Target sequences used for shRNA knockdown experiments listed in Supplementary Table 14.

Total RNA extraction and RT-PCR

Total RNA isolation and DNaseI treatment was performed using the Direct-zol RNA MiniPrep kit (R2053, Zymo Research) as per the manufacturer's protocol. Reverse transcription of 1 µg of RNA per sample was performed using SuperScript IV Vilo (11756050, Thermo Fisher Scientific) as per the manufacturer's protocol and quantified by spectrophotometer (ND1000 NanoDrop). From 5 ng to 10 ng of cDNA was used to perform quantitative PCR (qPCR) using SYBR Select Master Mix (4472908, Thermo Fisher Scientific). All the qPCR amplifications were performed in the Step One Plus system (Applied Biosystems).

Gene expression values were calculated by the $\Delta\Delta C_q$ method, using *GAPDH* as the housekeeping gene, and resulting experimental target values were normalized to the global mean of the control group. Normalized fold change was plotted using GraphPad Prism software. The sequences of the primers used in this study are listed in Supplementary Table 15.

In vitro studies and viability assays

Approximately 2,500 cells were plated in triplicates in 96-well plates for 5 days. For in vitro experiments, cells were treated with 50 nM GSK-LSD1 (SML1072, Sigma-Aldrich), 50 nM bomedemstat (IMG-7289; HY-109169B, MedChem Express), 500 nM TAK-418 (HY-138830, MedChem Express), 100 nM LY2090314 (HY-16294, MedChem Express) and 100 nM melagrusib (9-ING-41; HY-113914, MedChem Express).

Cell viability was determined using a Cell Titer-Glo luminescent cell viability assay (G7572, Promega). Data were presented as proliferation present by comparing the treated groups with the vehicle-treated cells.

Colony-forming unit assay

Leukaemia cell lines. Approximately 1,000 cells (for human leukaemia cell lines) and 500 cells (for mouse leukaemia cell lines) were initially plated in triplicates in the methylcellulose medium (MethoCult GF, H4435, StemCell Technologies) pre-added with vehicle, GSK-LSD1, LY2090314 or a combination of inhibitors. For serial replating, cells isolated from colonies in the previous plating were seeded again in the same semi-solid medium. Colony-forming units were scored every 7–10 days post-seeding.

Human CD34⁺ umbilical cord blood cells. Human cord blood CD34⁺ cells (200–0000, StemCell Technologies) were plated in methylcellulose (MethoCult H4534 Classic, StemCell Technologies). For each condition 5,000 cells were plated in 35-mm dishes in the presence of inhibitors. After 14 days, haematopoietic colonies were scored.

Human primary AML samples. Patient samples were thawed and cultured in StemSpan SFEM II (StemCell Technologies) supplemented with human recombinant Flt3/Flk-2, human recombinant IL-3, human recombinant GM-CSF, human recombinant IL-6, human stem cell factor and human recombinant G-CSF (StemCell Technologies) for 24 h. The cells were then treated with DMSO or inhibitors in methylcellulose medium (MethoCult H4535 or MethoCult H4534 Classic, StemCell Technologies) plated at 25,000 cells per millilitre on 35-mm culture dish and cultured for 7–10 days to form colonies.

Wright–Giemsa staining

The cells collected from culture plates were spun onto a cytological slide by using a cytospin centrifuge (Cytospin 4 Cytocentrifuge). Then, slides were stained using the May–Grünwald–Giemsa staining method. The fixed cells were stained for 8 min in May–Grünwald stain (MG500, Sigma-Aldrich), then slides were sequentially washed 6 times

in deionized water and then incubated for 30 min with Giemsa stain (1092041000, Sigma-Aldrich) and diluted with 19 volumes of distilled water. After this step, the cytological slides were rinsed again three times in distilled water and air dried. For long-time storage, a coverslip was attached to the slides by Eukitt mounting medium, which is an adhesive and specimen preservative that can be used manually and in automated coverslipping equipment. The slides were scanned using the NanoZoomer S210 slide scanner.

TCF/LEF luciferase reporter assay

HCT116 and THP-1 cells were plated at 100,000 cells per well in 12-well plates, and following a 24-h incubation were infected with 30 µl TCF/LEF luciferase reporter lentivirus (BPS Biosciences). Following 48 h, cells were replated and selected for 3 days using puromycin. Then, cells treated with inhibitors in the presence and absence of WNT3A (40 ng ml⁻¹) for 5 days. TCF/LEF activity was assessed using ONE-Step Luciferase reagent per recommended protocol (BPS Biosciences).

RNA-seq protocol and analysis

For freshly cultured cells, total RNA isolation and DNaseI treatment were performed using the Direct-zol (TM) RNA MiniPrep kit (R2053, Zymo Research) as per the manufacturer's protocol. Library preparation was conducted using the NEBNext UltraII RNA library kit (E7770S/L, NEB). Sequencing was conducted on an Illumina NextSeq 2000.

For ER-HOXA9 cell RNA-seq analysis, Fastq reads were aligned to the mouse genome (mm10) using STAR 2.7.0f. Read counts were mapped to genes using featureCounts. Differential analysis of gene expression was performed using DESeq2 (1.34.0). Only genes with more than 10 total counts when summed across all samples were considered. For THP-1 RNA-seq analysis, RNA-seq analysis was conducted using the EdgeR (3.50.3) limma (3.36.0) workflow. Reads were quantified using featureCounts, creating the raw gene count matrix. Data-quality metrics were investigated, and the limma voom normalization was applied to obtain counts per million (CPM) normalization and trimmed means of M values and normalization to finalize the differential expression analysis. The normalization accounted for sequencing depth. The log-CPM values were calculated, and adjusted $P < 0.01$ were considered significant. Genes responding synergistically to combo treatment were defined as those with adjusted $P < 0.01$ and fold change > 3 in combo versus vehicle and were also not significant at adjusted $P < 0.01$ and fold change > 1.5 in either GSK-LSD1 or LY2090314 versus vehicle. In THP-1 cells, genes responding synergistically to combo treatment were defined as those with adjusted $P < 0.01$ and more than 3× change in combo versus vehicle and not significant at $P < 0.05$ (non-adjusted) in either GSK-LSD1 or LY2090314 versus vehicle in THP-1 cells. Heatmaps of synergy genes and other gene lists were generated using Heatmapper.ca using Pearson correlation and average linkage settings. For pathway-level analysis, gene lists were either submitted to EnrichR^{72–74} or GSEA^{75,76} (4.3.3) was used. For GSEA, CPM-normalized data were used as inputs and GSEA MSigDB (2024.1) gene set compendia, or manually curated gene sets were used for enrichment using genes for permutations and default settings. Manually curated gene sets not in the MSigDB database included the Sykes terminal differentiation gene sets²⁴, the LSC47 leukaemia stem cell signature⁷⁷ and the Somerville leukemia stem cell signatures⁷⁸.

ATAC-seq protocol and analysis

ATAC-seq was performed as previously described²³. In brief, cells were treated with DNaseI (EN0521, Life Tech) to remove genomic DNA contamination. Live cell samples were quantified and assessed for viability and after cell lysis and cytosol removal, nuclei were treated with Tn5 enzyme (20034197, Illumina) for 30 min at 37 °C and purified with the Minelute PCR Purification Kit (28004, Qiagen) to produce tagmented DNA samples. Tagmented DNA was barcoded with Nextera Index Kit v2 (FC-131-2001, Illumina) and amplified via PCR before an SPRI Bead cleanup to yield purified DNA libraries. Sequencing was performed on

an Illumina HiSeq instrument (4000 or equivalent). Fastq files were subjected to quality control with FastQC (0.11.9) and then trimmed with Cutadapt (2.1) with reads less than 20 nucleotides being filtered out. Reads were then mapped against mm10 with Bowtie2 (2.4.4), and duplicate reads were removed with samtools (1.15.1) rmdup, and bam files were converted to bed files with bedtools (2.30.0) bamtobed. Peaks were then called with MACS2 (2.2.7.1) with replicates being merged for downstream analyses. For heatmaps and PCAs, matrices were generated with deeptools (3.5.1) computeMatrix, and heatmaps and PCAs were generated with deeptools plotHeatmap and ggplot2 (3.4.2), respectively. IFN α signal profiles were generated with deeptools plotHeatmap using the *IFNA* promoter regions as an input. *IFNA* promoters were extracted using the ChIPseeker (1.42.0) R (4.3.0) package. ATAC-seq tracks were visualized with Integrative Genomics Viewer (2.16.2). Homer (5.1) was used for motif enrichment analyses using default settings. All operations were performed using default settings unless otherwise noted.

CUT&RUN protocol and analysis

In brief, 250,000 cells were washed in 1 ml of wash buffer (20 mM HEPES pH 7.5, 0.5 mM spermidine and 120 mM NaCl) and centrifuged at 600g at room temperature three times, and the pellet were resuspended in 100 μ l of wash buffer per reaction. Following this, 10 μ l activated concavalin A beads per reaction was added, and the mixture was incubated at room temperature for 10 min with intermittent shaking. Captured cells were resuspended in 50 μ l of antibody-binding buffer (wash buffer with digitonin 0.05% and EDTA). Primary antibodies, including negative and positive controls, were added, and the tubes were nutated overnight at 4 °C. On the following day, the samples were washed twice in dig wash buffer (wash buffer with 0.05% digitonin), and a master mix of pAG-MNase was prepared and added to each sample. After nutating at 4 °C for 1 h, the samples were washed to remove unbound pAG-MNase. Tubes were cooled to 0 °C for 5 min, then supplemented with CaCl₂ to promote MNase digestion at 4 °C for 2 h followed by the addition of 2X STOP buffer (340 mM NaCl, 20 mM EDTA, 4 mM EGTA and 0.05% digitonin) and incubation at 37 °C for 10–15 min. Following a brief spin and magnetic separation, the supernatant containing enriched target-bound chromatin was proceeded directly with DNA cleanup with the Zymo DNA Clean&Concentrator-5 kit (Zymo Research). DNA libraries were prepared by the NEBNext Ultra II DNA library kit (E7645S) as per the manufacturer's instructions.

CUT&RUN samples were processed via Nextflow (21.10.6), using the nf-core CUT&RUN pipeline (v3.0.0)⁷⁹. Samples were aligned to the hg38 reference genome. Adapters were trimmed using Trim Galore (0.6.6), and paired-end alignment was performed using Bowtie2 (2.4.4). Mapping rates, GC content and other sample quality metrics were derived from nf-core via MultiQC. Peak calling was finalized using SEACR⁸⁰ (1.3) with a standard peak threshold of 0.05 and spike-in calibration performed with the *Saccharomyces cerevisiae* genome. Heatmap and PCA analyses by gene and peak were performed using deepTools (3.5.1). Downstream peak-based analyses were done with peak bed files from replicate experiments being merged. Merging was done using bedTools (2.30.0) concatenate to combine peak files, bedTools sort to order peaks, and bedTools merge to merge peak regions. Motif enrichment analysis, track visualization and signal over gene set promoter regions (IFN α and Sykes myeloid differentiation top 200 gene promoter regions) were done as described in the ATAC-seq analysis section in the Methods. Genomic distribution analyses were done with the ChIPseeker (1.42.0) R (4.3.0) package, and peak and gene overlaps were quantified with bedTools intersect. The sequences of the primers used for CUT&RUN-qPCR are listed in Supplementary Table 16.

Clinical dataset survival analysis

Patient data used in this study were taken from the cohort used in Bottomly et al.⁸¹ and referred to as the OHSU patient dataset. For signature

score analyses, patients were scored according to their match in expression to a list of signature genes (upregulated genes only, downregulated genes only or both upregulated and downregulated genes) using the singscore (1.26.0) R (4.3.0) package⁸². If upregulated signature genes only were used, the patient score is high if the patient upregulates those genes. If downregulated signature genes only were used, the patient score is high if the patient downregulates those genes. If both upregulated and downregulated signature genes were used, the upregulated gene score and downregulated gene scores are combined. Pearson correlation was used to quantify correlations between signature scores among the patients. Components of signatures used for score correlations in Fig. 5j were: upregulated genes of the ER-HOXA9 synergy signature and downregulated genes of the Somerville LSC signature (upper left); downregulated genes of the ER-HOXA9 synergy signature and total score of the MSigDB Wnt Signaling signature (upper right); upregulated and downregulated genes of the ER-HOXA9 synergy signature and upregulated genes of the MSigDB Hallmark Interferon Alpha Response signature (lower left); and upregulated genes of the MSigDB Hallmark Interferon Alpha Response signature and downregulated genes of the Somerville LSC signature (lower right). For survival analyses, Kaplan–Meier plotting was performed using the ggsurvplot function of the survminer R (4.3.0) package. Patients were stratified by median synergy score enrichment using the downregulated genes of the ER-HOXA9 synergy signature. Statistical significance of survival data was tested with log-rank tests using the survdiff function of the Survival (3.8-3) R (4.3.0) package.

Immunoblotting

Cells were lysed in a lysis buffer (0.1% SDS, 400 mM NaCl, 1 mM EDTA, 50 mM Tris-HCl and 1% Triton) plus protease inhibitor cocktail (11836170001, Sigma-Aldrich). Protein quantification was performed using a BCA assay (Promega). Of proteins, 20–40 μ g was mixed with Laemmli (Bio-Rad) and denatured for 10 min at 95 °C. Cell lysates were loaded onto each lane of a 4–20% Mini-PROTEAN TGX Gel (Bio-Rad). The proteins were then transferred to a Trans-Blot Turbo Midi Nitrocellulose Transfer membrane (Bio-Rad). Following this, the membrane was blocked using 5% BSA and incubated with primary antibodies overnight at 4 °C. The next day, after three washes with 1% TBS-T (each wash 10 min), membrane was incubated with the proper secondary HRP antibodies, diluted in 5% BSA, for 30–60 min at room temperature. The membrane was washed again with 1% TBS-T three times, and ECL was applied for membrane development. The Bio-Rad Chemi-Doc was used for the acquisition of western blot images. Antibodies included: β -catenin (D10A8) (dilution 1:1,000; 8480S, Cell Signaling), IRF-7 antibody (F-1; dilution 1:1,000; sc-74471, Santa Cruz Biotechnology), α -tubulin (DM1A; dilution 1:1,000; sc-32293, Santa Cruz Biotechnology), vinculin (42H89L44; dilution 1:1,000; 700062 Thermo Fisher Scientific), β -actin (13E5; dilution 1:1,000; 4970S, Cell Signaling), GSK3 α (dilution 1:1,000; 9338, Cell Signaling), GSK3 β (D5C5Z; dilution 1:1,000; 12456, Cell Signaling), anti-GSK3 α and anti-GSK3 β (phospho-Y216 + Y279) antibody (M132; dilution 1:1,000; ab45383, Abcam), STAT1 (dilution 1:1,000; 9172, Cell Signaling), phospho-STAT1 (Tyr701) monoclonal antibody (STIP-11A5; dilution 1:1,000; 33-3400, Thermo Fisher Scientific), anti-rabbit IgG, HRP-linked antibody (dilution 1:5,000; 7074S, Cell Signaling) and anti-mouse IgG, HRP-linked antibody (dilution 1:5,000; 7076S, Cell Signaling).

Immunoprecipitation

Of cleared protein lysate, 1.5–2 mg was used per immunoprecipitation (IP) in IP buffer (10 mM Tris-HCl pH 7.6, 150 mM NaCl and 0.2% NP-40) supplemented with Halt Protease and Phosphatase Inhibitor Cocktail (78445, Thermo Fisher Scientific). Of IP volume, 10% was designated for input assessments. Protein lysate was immunoprecipitated with 10 μ g of antibody pre-bound to 30 μ l of washed protein G Dynabeads (Invitrogen) per IP. IPs were conducted overnight at 4 °C, washed three times

Article

with IP buffer and once with the IP wash Buffer (10 mM Tris-HCl pH 7.6, 250 mM NaCl and 0.2% NP-40), both supplemented with Halt Protease and Phosphatase Inhibitor Cocktail (78445, Thermo Fisher Scientific). Then IPs were eluted in Laemmli buffer by boiling, then isolated from beads and transferred to new tubes for western blot analysis.

Software and statistical analysis

All experiments were performed with at least three replicates, with the specific number of replicates stated in the figure legends. Unless otherwise stated, statistical analyses were performed using GraphPad prism (v10.3.0) using two-way ANOVA, and statistical significance was determined at a $P < 0.05$.

Related to Fig. 5a–c, note that in the boxplots, the middle line represents the median, the lower and upper hinges represent the 25th and 75th percentiles, respectively, the lower whisker extends from the lower hinge to the smallest value at most $1.5 \times$ the interquartile range of the hinge, and the upper whisker extends from the upper hinge to the largest value no further than $1.5 \times$ the interquartile range of the hinge. Data beyond the whiskers are outliers that are plotted individually.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

RNA-seq data for ER-HOXA9 cells treated with inhibitors have been deposited under GSE249879. ATAC-seq data for ER-HOXA9 cells treated with inhibitors have been deposited under GSE249773. CUT&RUN and RNA-seq data for THP-1 cells treated with inhibitors have been deposited under GSE251860. The OHSU clinical dataset of patients with AML⁸¹ was downloaded from cBioPortal (https://www.cbioportal.org/study/summary?id=aml_ohsu_2022). GSEAs utilized the Molecular Signatures Database (MSigDB) (<https://www.gsea-msigdb.org/gsea/msigdb>)^{75,83,84}. Additional pathway enrichment analyses utilized the EnrichR database (<https://maayanlab.cloud/Enrichr/>)^{72–74}. Source data are provided with this paper.

69. He, L. et al. Methods for high-throughput drug combination screening and synergy scoring. *Methods Mol. Biol.* **1711**, 351–398 (2018).
70. Karjalainen, R. et al. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. *Blood* **130**, 789–802 (2017).
71. Schreurs, R. R. C. E., Baumdick, M. E., Drewniak, A. & Bunders, M. J. In vitro co-culture of human intestinal organoids and lamina propria-derived CD4⁺ T cells. *STAR Protoc.* **2**, 100519 (2021).
72. Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics* **14**, 128 (2013).
73. Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res.* **44**, W90–W97 (2016).
74. Xie, Z. et al. Gene set knowledge discovery with Enrichr. *Curr Protoc.* **1**, e90 (2021).
75. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl Acad. Sci. USA* **102**, 15545–15550 (2005).
76. Mootha, V. K. et al. PGC-1 α -responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat. Genet.* **34**, 267–273 (2003).

77. Huang, B. J. et al. Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia. *Nat. Commun.* **13**, 5487 (2022).
78. Somervaille, T. C. P. et al. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. *Cell Stem Cell* **4**, 129–140 (2009).
79. Ewels, P. A. et al. The nf-core framework for community-curated bioinformatics pipelines. *Nat. Biotechnol.* **38**, 276–278 (2020).
80. Meers, M. P., Tenenbaum, D. & Henikoff, S. Peak calling by sparse enrichment analysis for CUT&RUN chromatin profiling. *Epigenetics Chromatin* **12**, 42 (2019).
81. Bottomly, D. et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. *Cancer Cell* **40**, 850–864.e9 (2022).
82. Foroutan, M. et al. Single sample scoring of molecular phenotypes. *BMC Bioinformatics* **19**, 404 (2018).
83. Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. *Bioinformatics* **27**, 1739–1740 (2011).
84. Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst.* **1**, 417–425 (2015).

Acknowledgements We thank members of the Shi laboratory, especially B. Zee for helpful discussion; the Stem Cell and Xenograft Core of the Perlman School of Medicine for samples (RRID: SCR_010035); the FIMM High Throughput Biomedicine Unit for preparation of drug plates; Finnish Hematology Registry and Biobank for samples from patients with AML and associated data; and S. N. Constantinescu, T. Milne, A. Jambhekar, S. B. Lovitch and M. Carroll for providing feedback and helpful discussions. This work was supported by Ludwig Institute for Cancer Research core funding and in part by NIH/NCI R35CA210104 (to Y. Shi), NIH/NCI R01 CA279317-01 (to M.A.B.), the Research Council of Finland grants 357686, 334781, 352265 and 320185 (to C.A.H.), the Cancer Foundation Finland (to C.A.H.) and the Sigrid Jusélius Foundation (to C.A.H.). N.S. is supported by the UKRI AMLAC CDT, EPSRC grant EP/S023992/1. B.P. receives funding from the National Institute for Health Research, Oxford Biomedical Research Centre and the Cancer Research UK Senior Cancer Fellowship.

Author contributions A.H., A.D., M.A.B. and Y. Shi conceived the project, study design and experiments, and wrote the manuscript. All authors contributed to the completion of the manuscript. A.D. performed the drug compound screening. A.H. and A.D. performed the in vitro experiments. A.H. and A.D. performed the in vivo experiments with help from S.N. and Y.Y. A.H., A.D., B.V., I.J. and Y. Shi contributed to designing the in vivo experiments. A.H. and A.D. performed RNA-seq, ATAC-seq and CUT&RUN. M.A.B. performed the bioinformatics data analysis with support from N.S., A.J. and M.L.J.A. who was supervised by B.R. Ex vivo experiments on primary patient samples were conducted by N.I., A.H. and K.C.K. with supervision by C.A.H., A.M. and Y. Shi. Organoid experiments with primary patient samples were conducted by Y. Shen with supervision by B.P. LSK cell sorting and colony formation were conducted by A.H., S.N. and Y.L. A.H. and F.W. generated the GSK3 α -knockdown and GSK3 β -knockdown cells and conducted the experiments. Phospho-flow experiments on primary patient samples were conducted by N.I. and P.S. with supervision by C.A.H. P.V. contributed to discussions and writing of the manuscript.

Competing interests Y. Shi is a co-founder of K36 Therapeutics, Alternative Bio (ABio); a member of the Scientific Advisory Boards of K36 Therapeutics, ABio, Epigenica AB and Epic Bio; a board member of ABio and Epigenica AB; holds equity in Active Motif, K36 Therapeutics, Epic Bio, ABio and Epigenica AB; and serves on the Scientific Advisory Boards of School of Life Sciences, Westlake University and Westlake Laboratory of Life Sciences and Biomedicine, and Norway Centre for Embryology and Healthy Development. C.A.H. has received funding from Kronos Bio, Novartis, Oncopeptides, WNTResearch and Zentalis Pharmaceuticals for research unrelated to this study; and speaker and advisory fees from Amgen and Autolus. B.P. is a cofounder and equity holder in Alethiomics, a spin-out company from the University of Oxford; has received research funding from Alethiomics, Incyte and Galacto; and honoraria for consulting and/or paid speaking engagements from Incyte, Constellation Therapeutics, Blueprint Medicines, Novartis, GSK and BMS. All other authors declare no competing interests.


Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41586-025-08915-1>.

Correspondence and requests for materials should be addressed to Caroline A. Heckman, M. Andrés Blanco or Yang Shi.

Peer review information Nature thanks the anonymous reviewers for their contribution to the peer review of this work.

Reprints and permissions information is available at <http://www.nature.com/reprints>.




Extended Data Fig.1 | See next page for caption.

Article

Extended Data Fig. 1 | High-throughput screening identifies LY2090314 as an enhancer of LSD1-mediated differentiation. **a**, ER-HoxA9 as a cellular model for a phenotypic screen of AML differentiation. upon differentiation, ER-HoxA9 cells upregulate GFP fluorescence. The illustrations of the cells were created using BioRender (<https://biorender.com>). **b**, The small molecule library was pin-transferred into 96-well plates containing ER-HoxA9 cells in media with 50 nM GSK-LSD1. Plates were incubated for 5 days, and differentiation was evaluated by GFP expression and cell-surface marker CD11b. The schematic


was created using BioRender (<https://biorender.com>). **c**, The GSK3 inhibitor, LY2090314, showed the strongest synergy with 50 nM GSK-LSD1 to induce differentiation in ER-HoxA9 cells over 5 days of in vitro culture. **d**, Quantification of colonies formed by ER-HoxA9 cells treated with indicated inhibitors. Data are $\pm$ SD of six biological independent experiments. *P*-values were determined using two-way analysis of variance (ANOVA). **e**, Morphology of ER-HoxA9 colonies treated with indicated inhibitors. Representative micrographs from (**d**). Scale bars, 50 μ m. The experiment was repeated three times with similar results.



Extended Data Fig. 2 | See next page for caption.

Extended Data Fig. 2 | LSD1 and GSK3 inhibitors potentially synergize in different AML cell lines. **a.** Synergy plot using an HSA model for THP-1, Kasumi-1, U937, MOLM-13, OCI-AML3 and OCI-AML2 cells treated with different concentrations of GSK-LSD1 and LY2090314 for 5 days. **b.** Analysis of *CD11b* mRNA relative levels in U937 cells treated with the indicated inhibitors for 5 days. Values were normalized against *GAPDH*. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA). **c.** Analysis of CD11b cell-surface protein relative levels in U937 cells treated with the indicated inhibitors for 5 days. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA). **d.** Analysis of *CD11b* mRNA relative levels in human AML cells treated with the indicated inhibitors for 5 days. Values were normalized against *GAPDH*. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA). **e.** Analysis of THP-1 cell viability after treatment with IMG-7289, LY2090314 or combination

of both inhibitors for 5 days by Cell-Titer-Glo assay. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA). **f.** Analysis of *CD11b* mRNA relative levels in THP-1 cells treated with IMG-7289, LY2090314 or combination of both inhibitors for 5 days. Values were normalized against *GAPDH*. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA). **g.** Analysis of THP-1 cell viability after treatment with TAK-418, LY2090314 or combination of both inhibitors for 5 days by Cell-Titer-Glo assay. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA). **h.** Analysis of *CD11b* mRNA relative levels in THP-1 cells treated with TAK-418 or LY2090314 and combination of both inhibitors for 5 days. Values were normalized against *GAPDH*. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA).




Extended Data Fig. 3 | See next page for caption.

Article

Extended Data Fig. 3 | Combo treatment triggers transcriptional changes associated with myeloid differentiation and interferon response in AML cells. **a**, GSEA of 47-gene leukemia stem cell (LSC) signature in ER-HoxA9 cells treated with drug combo vs. vehicle. **b**, PCA of RNA-seq of THP-1 cells treated with vehicle, GSK-LSD1, LY2090314 or combination of both inhibitors. **c**, GSEA of myeloid maturation signatures in drug-treated THP-1 cells. **d**, GSEA of additional myeloid maturation signatures in THP-1 cells treated with combo vs. vehicle. **e**, GSEA of Somerville leukemia stem cell (LSC) signatures in THP-1 cells treated with combo vs. vehicle. **f**, Western immunoblots for β -catenin, phospho-GSK3 α/β (Y279/Y216), IRF7 and vinculin after treatment with the indicated inhibitors for 3 days in THP-1 cells. Vinculin was used as a loading control. The experiment was repeated three times with similar results. **g**, GSEA of Wnt and β -catenin signaling genes in ER-HoxA9 cells treated with drug combo vs. vehicle. **h**, GSEA of Wnt and β -catenin signaling genes in THP-1 cells treated with drug combo vs. vehicle. **i**, Expression of *TCF7* (TCF1) in drug-treated ER-HoxA9 cells. Data are presented as mean values $\pm$ SD from three independent biological replicates. *P*-values indicate the significance of unpaired, two-tailed Student *t*-tests. “ns” indicates not significant. **j**, Heatmap of expression of genes synergistically upregulated or downregulated upon combo treatment (left),

and type I interferon signature genes (right). **k**, Expression of genes relating to the type I interferon response in drug-treated THP-1 cells. Data are presented as mean values $\pm$ SD from three independent biological replicates. *P*-values indicate the significance of unpaired, two-tailed Student *t*-tests. See source data for individual *P*-values. Asterisks indicate significance at these levels: **P* < 0.05, ***P* < 0.01, ****P* < 0.001, *****P* < 0.0001, “ns” indicates not significant. **l**, EnrichR database pathways enriched in upregulated combo synergy signature genes. Significance of enrichment *z*-scores is shown as *q*-values (corresponding to *p*-values adjusted for significance by Benjamini-Hochberg method). **m**, Dot blot for dsRNA using total RNA from THP-1 cells treated with indicated inhibitors for 3 days. Total RNA extract treated with mock, RNase T1, RNase III, or RNase A (350 mM NaCl) was dotted on Hybond N+ membranes, visualized by methylene blue staining and immunoblotted with J2 antibody. **n**, Table shows rank and *P*-value of enrichment of top transcription factor (TF) motifs in accessible chromatin of ER-HoxA9 cells treated with vehicle, GSK-LSD1, LY2090314 or combination of both inhibitors. Motifs shown in all treatments are the top 10 motifs from combo-treated cells. Enrichment rank and *P*-values of *TCF7* (TCF1) and LEF motifs are also shown. Motif enrichment significance was determined via hypergeometric tests.




Extended Data Fig. 4 | See next page for caption.

Extended Data Fig. 4 | Combo treatment activates type I interferon

signaling in AML cells. a, b, c, Analysis of *ISG15* and *MXI* mRNA relative levels in THP-1 (**a**), MOLM-13 (**b**) and U937 (**c**) cells treated with indicated inhibitors. Values were normalized against *GAPDH*. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA). **d,** CUT&RUN-qPCR occupancy analysis of β -catenin on promoter of *STAT1*, *IFIH1* and *STAT2* in OCI-AML3 cell treated with indicated inhibitors. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA). **e,** CUT&RUN-qPCR occupancy analysis of IRF7 on promoter of *STAT1*, *IFIH1* and *STAT2* in OCI-AML3 cell treated with indicated inhibitors. Data are presented as mean $\pm$ SD of 3 biological independent


experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA). **f,** CUT&RUN-qPCR occupancy analysis of β -catenin on promoter of *STAT1*, *IFIH1* and *STAT2* in MOLM-13 cell treated with indicated inhibitors. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA). **g,** CUT&RUN-qPCR occupancy analysis of IRF7 on promoter of *STAT1*, *IFIH1* and *STAT2* in MOLM-13 cell treated with indicated inhibitors. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA). **h,** Scatter correlation plot of H3K4me1 and mRNA expression in THP-1 cells treated with combo. R indicates Pearson correlation value. “ns” indicates not significant.



Extended Data Fig. 5 | See next page for caption.

Extended Data Fig. 5 | The impact of combo treatment is significantly diminished by the inhibition of STAT1 activation. **a**, Western blot analysis of p-STAT1 (Y701) and total STAT1 from THP-1 cells treated with indicated inhibitors in the presence or absence of ruxolitinib for 5 days. Tubulin was used as a loading control. The experiment was repeated three times with similar results. **b**, Analysis of *IRF7*, *ISGL1*, *MX1* and *DDX58* mRNA relative levels in THP-1 cells treated with indicated inhibitors in the presence or absence of ruxolitinib for 5 days. Values were normalized against *GAPDH*. Data are presented as mean $\pm$ SD of 3 biological independent experiments (n = 3). *P*-values were determined using two-way analysis of variance (ANOVA). **c**, Analysis of cell viability in THP-1 cells treated with the indicated inhibitors in the presence or absence of ruxolitinib for 5 days by Cell-Titer-Glo assay. Data are presented as mean $\pm$ SD of 3 biological independent experiments (n = 3). *P*-values were determined using two-way analysis of variance (ANOVA). **d**, Analysis of *CD11b* mRNA relative levels in THP-1 cells treated with the indicated inhibitors in the presence or absence of ruxolitinib for 5 days. Data are presented as mean $\pm$ SD of 3 biological independent experiments (n = 3). *P*-values were determined using two-way analysis of variance (ANOVA). **e**, Representative images of THP-1 cells treated with indicated inhibitors in the presence or absence of ruxolitinib for 5 days and stained with Wright-Giemsa. Scale bars, 25 μ m. The experiment was repeated three times with similar results. **f**, Analysis of *ISGL1* and *MX1* mRNA relative levels in MOLM-13 cells treated with indicated inhibitors in the presence or absence of ruxolitinib for 5 days. Values were normalized against *GAPDH*. Data are presented as mean $\pm$ SD of 3 biological independent experiments (n = 3). *P*-values were determined using two-way analysis of variance (ANOVA). **g**, Analysis of cell viability in MOLM-13 cells treated with the indicated inhibitors in the presence or absence of ruxolitinib for 5 days by Cell-Titer-Glo assay. Data are presented as mean $\pm$ SD of 3 biological independent experiments (n = 3). *P*-values were determined using two-way analysis of variance (ANOVA).


h, Analysis of *CD11b* mRNA relative levels in MOLM-13 cells treated with the indicated inhibitors in the presence or absence of ruxolitinib for 5 days. Values were normalized against *GAPDH*. Data are presented as mean $\pm$ SD of 3 biological independent experiments (n = 3). *P*-values were determined using two-way analysis of variance (ANOVA). **i**, Western blot analysis of STAT1 protein level in THP-1 cells. Two independent clones were used for *STAT1*-KO. Tubulin was used as a loading control. The experiment was repeated three times with similar results. **j**, Analysis of *IRF7*, *ISGL1*, *MX1* and *DDX58* mRNA relative levels in *STAT1*-KO THP-1 cells treated with indicated inhibitors for 5 days. Values were normalized against *GAPDH*. Data are presented as mean $\pm$ SD of 3 biological independent experiments (n = 3). *P*-values were determined using two-way analysis of variance (ANOVA). **k**, Analysis of cells viability in *STAT1*-KO THP-1 cells treated with indicated inhibitors for 5 days by Cell-Titer-Glo assay. Data are presented as mean $\pm$ SD of 3 biological independent experiments (n = 3). *P*-values were determined using two-way analysis of variance (ANOVA). **l**, Analysis of *CD11b* mRNA relative levels in *STAT1*-KO THP-1 cells treated with indicated inhibitors for 5 days. Data are presented as mean $\pm$ SD of 3 biological independent experiments (n = 3). *P*-values were determined using two-way analysis of variance (ANOVA). **m**, Analysis of β -catenin and IRF7 interactions by co-immunoprecipitation in THP-1 cells treated with indicated inhibitors for 5 days. Vinculin was used as a loading control. The experiment was repeated three times with similar results. **n**, CUT&RUN tracks of IRF7 and β -catenin at the *MYC* locus in drug-treated THP-1 cells. **o**, Enrichment of E2F motifs in genomic regions co-bound by IRF7 and β -catenin in combo-treated THP-1 cells. Motif enrichment significance was determined via hypergeometric tests. **p**, Top 7 ChipEnrich Hallmark database pathway enrichments in genes mapping to genomic regions co-bound by IRF7 and β -catenin in combo-treated THP-1 cells. *P*-values were determined via ChIP-Enrich method.



Extended Data Fig. 6 | See next page for caption.

Extended Data Fig. 6 | GSK3 α and GSK3 β depletion have distinct effects on β -catenin stabilization and their synergy with LSD1 inhibitor. **a,** Western blot analysis of GSK3 α and GSK3 β and β -Catenin protein level in THP-1 cells. Two independent clones were used for GSK3A-KD and GSK3B-KD. Vinculin was used as a loading control. The experiment was repeated three times with similar results. **b**, Analysis of cell viability in GSK3 α - and GSK3 β -depleted THP-1 cells using the Cell-Titer-Glo assay. Data are presented as mean $\pm$ SD of 3 biological independent experiments (n = 3). *P*-values were determined using two-way analysis of variance (ANOVA). **c**, Analysis of *CD11b* mRNA relative levels in GSK3 α - and GSK3 β -depleted THP-1 cells. Values were normalized against *GAPDH*. Data are presented as mean $\pm$ SD of 3 biological independent experiments (n = 3). *P*-values were determined using two-way analysis of variance (ANOVA). **d**, Representative images of GSK3 α - and GSK3 β -depleted THP-1 cells stained with Wright-Giemsa. Scale bars, 25 μ m. The experiment was repeated three times with similar results. **e**, Western blot analysis of β -Catenin, IRF7, Vinculin, β -Actin and GSK3 β protein level in THP-1 cells infected with shCTRL and shGSK3B and treated with indicated inhibitors for 3 days. Vinculin and β -Actin were used as loading controls. The experiment was repeated three times with similar results. **f**, Analysis of cell viability in THP-1 cells infected with shCTRL and shGSK3B and treated with indicated inhibitors for 5 days using the Cell-Titer-Glo assay. Data are presented as mean $\pm$ SD of 3 biological independent experiments (n = 3). *P*-values were determined using two-way analysis of

variance (ANOVA). **g**, Analysis of *CD11b* mRNA relative levels in THP-1 cells infected with shCTRL and shGSK3B and treated with indicated inhibitors for 5 days. Values were normalized against *GAPDH*. Data are presented as mean $\pm$ SD of 3 biological independent experiments (n = 3). *P*-values were determined using two-way analysis of variance (ANOVA). **h**, Western blot analysis of β -Catenin, IRF7, Vinculin, β -Actin, GSK3 β and GSK3 α protein level in THP-1 cells infected with shCTRL and shGSK3A and treated with indicated inhibitors for 3 days. Vinculin and β -Actin were used as loading controls. The experiment was repeated three times with similar results. **i**, Analysis of cell viability in THP-1 cells infected with shCTRL and shGSK3A and treated with indicated inhibitors for 5 days using the Cell-Titer-Glo assay. Data are presented as mean $\pm$ SD of 3 biological independent experiments (n = 3). *P*-values were determined using two-way analysis of variance (ANOVA). **j**, Analysis of *CD11b* mRNA relative levels in THP-1 cells infected with shCTRL and shGSK3A and treated with indicated inhibitors for 5 days. Values were normalized against *GAPDH*. Data are presented as mean $\pm$ SD of 3 biological independent experiments (n = 3). *P*-values were determined using two-way analysis of variance (ANOVA). **k**, Representative images of THP-1 cells infected with shCTRL, shGSK3B or shGSK3A, treated with the indicated inhibitors for 5 days, and stained with Wright-Giemsa. Scale bars, 25 μ m. The experiment was repeated three times with similar results. "ns" indicates not significant.




Extended Data Fig. 7 | See next page for caption.

Article

Extended Data Fig. 7 | Effect of the combo treatment in different primary AML samples. **a**, Quantification of colonies formed by a *NPM1*-mutant primary AML sample treated with DMSO, GSK-LSD1 (50 nM), LY2090314 (100 nM) or combination of both inhibitors. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA). **b**, Quantification of colonies formed by two different *DNMT3A*-WT primary AML samples treated with DMSO, GSK-LSD1 (50 nM), LY2090314 (100 nM) or combination of both inhibitors. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA). **c**, Quantification of colonies formed by two different *TP53*-mutant primary AML samples treated with DMSO, GSK-LSD1 (50 nM), LY2090314 (100 nM) and combination of both inhibitors. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA). **d**, Wright-Giemsa-stained cytopins for primary AML samples treated with DMSO, GSK-LSD1 (50 nM), LY2090314 (100 nM) and combination of both inhibitors. Scale bars, 25 μ m. The experiment was repeated three times with similar results. **e**, Wright-Giemsa-stained cytopins for a *DNMT3A*-mutant primary AML sample treated with DMSO, IMG-7289 (50 nM), 9-ING-41 (100 nM) and combination of both inhibitors. Scale bars, 25 μ m. The experiment was repeated three times with similar results. **f**, Fold change induction of β -catenin-positive cells in primary AML samples ($n = 5$ biologically independent samples) treated with Vehicle, GSK-LSD1 (50 nM), LY2090314


(100 nM) or combination of both inhibitors. For statistical analyses two-sided Mann Whitney U tests were used $^* = P < 0.05$. Comparisons: DMSO - LY2090314 p -value = 0.042, DMSO - Combo p -value = 0.042, GSK-LSD1 - LY2090314 p -value = 0.048, GSK-LSD1- Combo p -value 0.048. *P*-values were adjusted with Bonferroni method. In the boxplot, the middle line represents the median, the lower and upper hinges represent the 25th and 75th percentiles, the lower whisker extends from the lower hinge to the smallest value at most 1.5*inter-quartile range (IQR) of the hinge, the upper whisker extends from the upper hinge to the largest value no further than 1.5*IQR of the hinge. Data beyond the whiskers are outliers that are plotted individually. **g**, Analysis of *IRF7*, *ISG15*, *DDX58* and *MX1* mRNA relative levels in *DNMT3A*-mutant primary AML samples treated with DMSO, GSK-LSD1 (50 nM), LY2090314 (100 nM) or combination of both inhibitors. Values were normalized against *GAPDH*. Each dot represents one primary sample and $n = 3$ biological independent experiments. *P*-values were determined using two-way analysis of variance (ANOVA). **h**, Analysis of ERVs mRNA relative levels in *DNMT3A*-WT vs *DNMT3A*-mutant primary AML samples. Each dot represents one primary sample and $n = 3$ biological independent experiments. *P*-values were determined using two-way analysis of variance (ANOVA). **i**, Analysis of *IRF7*, *ISG15*, *DDX58* and *MX1* mRNA relative levels in a *DNMT3A*-WT vs *DNMT3A*-mutant primary AML samples. Values were normalized against *GAPDH*. Each dot represents one primary sample and $n = 3$ biological independent experiments. *P*-values were determined using two-way analysis of variance (ANOVA). "ns" indicates not significant.



Extended Data Fig. 8 | See next page for caption.


Extended Data Fig. 8 | Ruxolitinib treatment abrogates the effect of the combo treatment in primary AML samples. **a**, Quantification of colonies formed by a primary AML sample (6998) treated with DMSO, GSK-LSD1 (50 nM), LY2090314 (100 nM) or combination of both inhibitors in the presence or absence of ruxolitinib. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA). **b**, Analysis of *IRF7*, *ISG15*, *MX1* and *DDX58* mRNA relative levels in the primary sample (6998) treated with indicated inhibitors in the presence or absence of ruxolitinib. Values were normalized against *GAPDH*. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA). **c**, Analysis of *CD11b* mRNA relative levels in the primary sample (6998) treated with the indicated inhibitors in the presence or absence of ruxolitinib. Values were normalized against *GAPDH*. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA). **d**, Representative images of the AML primary sample (6998) treated with indicated inhibitors in the presence or absence of ruxolitinib and stained with Wright-Giemsa. Scale bars, 25 μ m. The experiment was repeated three times with similar results. **e**, Quantification of colonies formed by a primary AML sample (6349) treated with DMSO, GSK-LSD1 (50 nM), LY2090314 (100 nM) and combination of both inhibitors in the presence or absence of ruxolitinib. Data are presented as mean $\pm$ SD of 3 biological

independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA). **f**, Analysis of *IRF7*, *ISG15*, *MX1* and *DDX58* mRNA relative levels in the primary sample (6349) treated with indicated inhibitors in the presence or absence of ruxolitinib. Values were normalized against *GAPDH*. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA). **g**, Analysis of *CD11b* mRNA relative levels in the primary sample (6349) treated with the indicated inhibitors in the presence or absence of ruxolitinib. Values were normalized against *GAPDH*. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA). **h**, Representative images of the AML primary sample (6349) treated with indicated inhibitors in the presence or absence of ruxolitinib and stained with Wright-Giemsa. Scale bars, 25 μ m. *P*-values were determined using two-way analysis of variance (ANOVA). The experiment was repeated three times with similar results. **i**, Analysis of *CD11b* mRNA relative levels in CD34⁺ cells treated with the indicated inhibitors. Values were normalized against *GAPDH*. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA). “ns” indicates not significant. **j**, Morphology of CD34⁺ cells and their colonies treated with indicated inhibitors. Scale bars, 50 μ m for colonies morphology and 25 μ m for morphology of cells. The experiment was repeated three times with similar results.



Extended Data Fig. 9 | Combo treatment efficacy in vivo. **a**, Related to Fig. 5h. Representative images of spleen harvested from mice at the end of treatment in OCI-AML3 model. **b, c, d**, related to Fig. 5i. Body weight variance (**b**), representative bioluminescence images (**c**) and quantitative bioluminescence imaging data (**d**) for mice treated with indicated inhibitor in *DNMT3A*-mutant PDX sample, AML-579. **** = $p < 0.0001$. **e, f, g**, Kaplan–Meier survival curves (**e**), tumor burden (**f**) and body weight variance (**g**) of vehicle ($n = 4$), GSK-LSD1 ($n = 4$), LY2090314 ($n = 4$) or combination of both inhibitors ($n = 4$)–treated mice

in the *DNMT3A*-WT PDX sample, AML-372. Treatment was initiated 13 days after transplantation for two weeks. P -values were determined using the log-rank test. * = $p = 0.0344$, ** = $p = 0.0096$. **h**, Fold change in CD11b⁺ cells among patient-derived cells isolated from human organoids after 5 days of treatment with vehicle, GSK-LSD1, LY2090314 or combination therapy. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). P -values were determined using two-way analysis of variance (ANOVA).



Extended Data Fig. 10 | Combo treatment suppresses the Wnt pathway in AML and colorectal cells. **a**, Number of *DNMT3A*-WT and *DNMT3A*-mutant OHSU patients with high (upper quartile) combo synergy scores and low (quartiles 1-3) combo synergy scores. **b**, data in **(a)** shown via bar graph. *P*-value reports significance of overrepresentation of *DNMT3A* mutant patients in the synergy score high population using one-proportion z-tests. “ns” indicates not significant. **c**, Analyzing the TCF/LEF reporter activity in THP-1 cells following

treatment with indicated inhibitors, with and without the presence of WNT3a. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA). **d**, Analyzing the TCF/LEF reporter activity in HCT-116 cells following treatment with indicated inhibitors, with and without the presence of WNT3a. Data are presented as mean $\pm$ SD of 3 biological independent experiments ($n = 3$). *P*-values were determined using two-way analysis of variance (ANOVA).

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a	Confirmed
☐	☒ The exact sample size (<i>n</i>) for each experimental group/condition, given as a discrete number and unit of measurement
☐	☒ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
☐	☒ The statistical test(s) used AND whether they are one- or two-sided <i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>
☐	☒ A description of all covariates tested
☐	☒ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
☐	☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
☐	☒ For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
☒	☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
☒	☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
☐	☒ Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	No software was generated in this study. The Bio-Rad ChemiDoc was used for the acquisition of western blot images, and the Hamamatsu NanoZoomer S210 Slide Scanner for Cytospin slides scanning. Libraries for RNA-seq, CUT&RUN, and ATAC-seq were sequenced on the Illumina NextSeq 2000 and Illumina HiSeq 4000. Quantitative real-time PCR was conducted on the StepOnePlus instrument (Applied Biosystems). DNA/ RNA concentration measurements were performed using the Thermo Fisher NanoDrop Lite (ND1000). Bioluminescent imaging was collected using the IVIS Lumina system. Ex vivo drug sensitivity of primary AML cells was analyzed using the iQue Screener Plus-VBR flow cytometer, with gating performed using ForeCyt software version 9.0 (Intellicyt). For phosphoflow analysis, cells were analyzed on the iQue PLUS flow cytometer, and data were processed using ForeCyt software version 9.0. LSK cells were sorted using a FACS Aria Fusion (BD Bioscience).
Data analysis	Graph Pad Prism 10 was used for analysis of in vivo and in vitro phenotypic assays and for most of graph production and for the statistical test. Image J v1.54g was used for the analysis of colonies morphology images. R v4.2 was used to analyze flow cytometry and phosphoflow results from AML patient samples. For ER-Hoxa9 RNA-seq analysis, differential gene expression analysis was performed with DESeq2 (1.34.0). For THP-1 RNA-seq analysis, differential gene expression was performed with an EdgeR (3.50.3)-limma (3.36.0) workflow. Pathway analysis were performed with EnrichR and GSEA (4.3.3). For ATAC-seq, analysis was performed with FastQC (0.11.9), Cutadapt (2.1), Bowtie2 (2.4.4), samtools (1.15.1), bedtools (2.30.0), MACS2 (2.2.7.1), deeptools (3.5.1), ggplot2 (3.4.2), Homer (5.1), and the ChIPseeker (1.42.0) R (4.3.0) package. CUT&RUN samples were processed via Nextflow (21.10.6), using the nf-core CUT&RUN pipeline (v3.0.0) and further analyses were performed with Trim Galore (0.6.6), Bowtie2 (2.4.4), SEACR (1.3), deepTools (3.5.1), bedTools (2.30.0), and ChIPseeker (1.42.0). For clinical dataset survival analyses, the singscore (1.26.0) and Survival (3.8-3) R (4.3.0) packages were used.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

RNA-sequencing, ATAC-seq and CUT&RUN data have been deposited at the Gene Expression Omnibus (GEO) (<https://www.ncbi.nlm.nih.gov/geo/>) under the accession numbers GSE249879, GSE249773 and GSE251860. The OHSU clinical AML patient dataset was downloaded from cBioPortal (https://www.cbioportal.org/study/summary?id=aml_ohsu_2022). Gene Set Enrichment Analyses (GSEAs) utilized the Molecular Signatures Database (MSigDB) (<https://www.gsea-msigdb.org/gsea/msigdb>). Additional pathway enrichment analyses utilized the EnrichR database (<https://maayanlab.cloud/Enrichr/>).

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	Not reported in this study.
Reporting on race, ethnicity, or other socially relevant groupings	Not reported in this study.
Population characteristics	AML patient samples for ex vivo drug sensitivity analysis and phosphoflow experiments (n=17) were received from the Finnish Hematology Registry and Clinical Biobank. Samples were collected from patients whose disease status was either diagnosis (n=8), relapse (n=7) or refractory (n=2). Patients ages ranged from 40 to 76 years. Karyotype and mutation information was received from the hospital where the sample was collected, or it is based on whole exome sequencing data produced at the Institute for Molecular Medicine Finland. Karyotype and mutation data is provided in the supplemental Table S12. Only karyotype and mutation information were used to compare ex vivo drug sensitivity results.
Recruitment	Research material used in this project is based on an already existing cohort of samples from patients diagnosed with AML that was collected at the clinics in Finland and stored in liquid nitrogen at the Institute for Molecular Medicine Finland. Patient bone marrow or peripheral blood samples were taken in hospitals by skilled professionals after informed consent and using approved protocols in accordance with the Declaration of Helsinki. Samples were taken during routine diagnostic/treatment procedures to avoid additional procedures and inconvenience to the patients.
Ethics oversight	Samples were collected after informed consent from patients with AML using protocols approved by an Institutional Review Board at the Helsinki University Hospital (permit numbers 239/13/03/00/2010, 303/13/03/01/2011) in compliance with the Declaration of Helsinki.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Group sizes for the in vitro and in vivo validation experiments were selected based on prior knowledge of variation, leukemic cell engraftment and treatment with GSK-LSD1 and LY2090314. Sykes, D. B. et al. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia. <i>Cell</i> 167, 171-186.e15 (2016). Zamek-Gliszczyński, M., J. et al. Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure. <i>Drug Metab Dispos.</i> 41:714-26(2013). Zee, B. M. et al. Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia. <i>iScience</i> 24, 102651 (2021). Samples from patients with AML were chosen for flow cytometry based drug sensitivity analysis based on availability of the sample vials from donors with genetic aberrations or mutations of interest.
-------------	--

Data exclusions	No data was excluded from the analyses.
Replication	All attempts of replication were successful and described in the legends and method section.
Randomization	For in vivo experiments mice were age-matched and randomized. No other randomization was performed, as the remaining experiments were conducted in vitro using leukemic cell lines but these cells were seeded from the same cell solution across all relevant conditions to control for seeding density and population.
Blinding	Data collection and analysis did not involve any blinding procedures. The investigators were not blinded since the collected data relied on quantitative analysis.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
☐	☒ Antibodies
☐	☒ Eukaryotic cell lines
☒	☐ Palaeontology and archaeology
☐	☒ Animals and other organisms
☒	☐ Clinical data
☒	☐ Dual use research of concern
☒	☐ Plants

Methods

n/a	Involved in the study
☒	☐ ChIP-seq
☐	☒ Flow cytometry
☒	☐ MRI-based neuroimaging

Antibodies

Antibodies used

β-Catenin (D10A8) (dilution 1:1000, Cat:8480S, Cell Signaling, Lot: 9), IRF-7 Antibody (F-1) (dilution 1:1000, Cat: sc-74471, Santa Cruz Biotechnology, Lot: I1609), α-Tubulin (DM1A) (dilution 1:1000, Cat: sc-32293, Santa Cruz Biotechnology, Lot: I1521), Vinculin (42H89L44) (dilution 1:1000, Cat: 700062 Thermo Fisher Scientific, Lot: 2616511), β-Actin (13E5) (dilution 1:1000, Cat: 4970S, Cell Signaling, Lot: 19), GSK-3α (dilution 1:1000, Cat: 9338, Cell Signaling, Lot: 6), GSK-3β (D5C5Z) (dilution 1:1000, Cat: 12456, Cell Signaling, Lot: 10), Anti-GSK3 (alpha + beta) (phospho Y216 + Y279) antibody [M132] (dilution 1:1000, Cat: ab45383, Abcam, Lot: 1089746-1), STAT1 (dilution 1:1000, Cat: 9172, Cell Signaling, Lot: 29), Phospho-STAT1 (Tyr701) Monoclonal Antibody (ST1P-11A5) (dilution 1:1000, Cat: 33-3400, Thermo Fisher scientific, Lot:YL389734), Anti-rabbit IgG, HRP-linked Antibody (dilution: 1:5000, Cat: 7074S, Cell Signaling, Lot: 33) and Anti-mouse IgG, HRP-linked Antibody (dilution: 1:5000, Cat: 7076S, Cell Signaling, Lot: 38).

Flow cytometry antibodies for ex vivo drug sensitivity testing of AML samples: CD45-FITC (1:100 dilution, HI30, BD Pharmingen, 555482/561865), CD34-APC (1:100, 8G12, BD Pharmingen, 555824), CD15-PE-Cy7 (1:80, W6D3, Biolegend, 323030), CD14-BV421 (1:50, M5E2, BD Biosciences, 565283), CD11b-BV605 (1:80, ICRF44, BD Horizon, 562721), Annexin V (1:50, BD Pharmingen, 556422), 7-AAD (1:50, BD Pharmingen, 559925).

Antibodies for phosphoflow analysis of AML samples: CD45-BV786 (1:100, HI30, BD Biosciences, 563716), CD38-BV421 (1:100, HIT2, BD Biosciences, 562444), CD34-APC-Cy7 (1:100, 581, BioLegend, 343513) and CD11b-BV605 (1:100 ICRF44, BD Horizon, 562721), Zombie Yellow (1:100, BioLegend, 423103), β-catenin-AF488 (1:25, 14/Beta-Catenin, BD Pharmingen, 562505).

Validation

For each western blot a control has been included beside knock out samples on the same blot, further manufacturer validation statements are listed as follow:

β-Catenin (Cell Signaling, 8480): <https://www.cellsignal.com/products/primary-antibodies/b-catenin-d10a8-xp-rabbit-mab/8480>
IRF7 (Santa Cruz Biotechnology, SC-74471): <https://www.scbt.com/p/irf-7-antibody-f-1>

α-Tubulin (Santa Cruz Biotechnology, sc-32293): <https://www.scbt.com/p/alpha-tubulin-antibody-dm1a>

Vinculin (Thermo Fisher Scientific, 700062): <https://www.thermofisher.com/antibody/product/Vinculin-Antibody-clone-42H89L44-Recombinant-Monoclonal/700062>

STAT1 (Cell Signaling, 9172): <https://www.cellsignal.com/products/primary-antibodies/stat1-antibody/9172>

Phospho-STAT1 (Tyr701) (Thermo Fisher scientific, 33-3400): <https://www.thermofisher.com/antibody/product/Phospho-STAT1-Tyr701-Antibody-clone-ST1P-11A5-Monoclonal/33-3400>

β-Actin (Cell Signaling, 4970): <https://www.cellsignal.com/products/primary-antibodies/b-actin-13e5-rabbit-mab/4970>

srsltid=AfmBOordnCvdJ3ldEw7zGXh7O7zefLyPlafkRvORPrAd-l2DMnW-x4

GSK-3α (Cell Signaling, 9338): <https://www.cellsignal.com/products/primary-antibodies/gsk-3a-antibody/9338>

srsltid=AfmBOoruzqzjYeXhNfOFbTCaqDL_kIKpEhSz5uvswHfBuqHo7r3RcU-u

GSK-3β (D5C5Z) (Cell Signaling, 12456): <https://www.cellsignal.com/products/primary-antibodies/gsk-3b-d5c5z-xp-rabbit-mab/12456>?srsltid=AfmBOorVmJJ7mSEGjhR5EGo0i91VR0BrFsv0VeHopDmi_TYiFkNq8po2

GSK3 (alpha + beta) (phospho Y216 + Y279) antibody (Abcam, ab45383): <https://www.abcam.com/en-us/products/primary-antibodies/gsk3-alpha-beta-phospho-y216-y279-antibody-m132-ab45383>

Antibodies used for flow cytometry experiments with AML samples:

CD45-FITC: <https://www.bdbiosciences.com/en-eu/products/reagents/flow-cytometry-reagents/research-reagents/single-color->

antibodies-ruo/fitc-mouse-anti-human-cd45.555482
 CD34-APC: <https://www.bdbiosciences.com/en-eu/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/apc-mouse-anti-human-cd34.555824>
 CD15-PE-Cy7: <https://www.biolegend.com/en-us/products/pe-cyanine7-anti-human-cd15-ssea-1-antibody-8259>
 CD14-BV421: <https://www.bdbiosciences.com/en-eu/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/bv421-mouse-anti-human-cd14.565283>
 CD11b-BV605: <https://www.bdbiosciences.com/en-eu/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/bv605-mouse-anti-human-cd11b.562721>
 Annexin V: <https://www.bdbiosciences.com/en-eu/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/pe-annexin-v.556422>
 7-AAD: <https://www.bdbiosciences.com/en-eu/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/7-aad.559925>

Antibodies used for phosphoflow experiments with AML samples:
 CD45-BV786: <https://www.bdbiosciences.com/en-eu/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/bv786-mouse-anti-human-cd45.563716>
 CD38-BV421: <https://www.bdbiosciences.com/en-eu/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/bv421-mouse-anti-human-cd38.562444>
 CD34-APC-Cy7: <https://www.biolegend.com/en-us/products/apc-cyanine7-anti-human-cd34-antibody-6159>
 CD11b-BV605: <https://www.bdbiosciences.com/en-eu/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/bv605-mouse-anti-human-cd11b.562721>
 Zombie Yellow: <https://www.biolegend.com/en-gb/products/zombie-yellow-fixable-viability-kit-8514>
 β-catenin-AF488: <https://www.bdbiosciences.com/en-eu/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/alexa-fluor-488-mouse-anti-catenin.562505>

Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)	ER-HoxA9 cells were kindly provided by Dr.David T. Scadden. THP-1, MOLM-13, Kasumi-1, U937, OCI-AML2 and OCI-AML3 were obtained from Dana Farber Cancer Institute or Dr.David T. Scadden's group or purchased from DSMZ. HCT-116 cells were kindly provided by Dr. Parinaz Mehdipour, who purchased them from ATCC (ATCC-CCL-247).
Authentication	Authenticated using STR DNA profiling.
Mycoplasma contamination	The cells were confirmed to be negative for mycoplasma.
Commonly misidentified lines (See ICLAC register)	None.

Animals and other research organisms

Policy information about [studies involving animals; ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals	6 to 8 weeks old female C57BL/6J mice purchased from Jackson Laboratory. For OCI-AML3 and PDX samples, 6- to 8-week-old NSG (NOD.Cg-PrkdcSCID Il2rgtm1Wjl/SzJ) mice were purchased from Charles River. All cages were on a 12 h:12 h light: dark cycle (lights on, 07:00) in a temperature-controlled and humidity-controlled room. Room temperature was maintained at 19-23 °C, and room humidity was maintained at 45–65%.
Wild animals	No wild animal were used in this study.
Reporting on sex	All female mice were used to make sure the mouse model is truly syngeneic as the original ER-HoxA9/MEIS1 AML cells were derived from a female mouse. For OCI-AML3 cells both male and female mice were used.
Field-collected samples	No field-collected samples were used in this study.
Ethics oversight	Animals were maintained at Boston Children Hospital's ARCH facility and treated according to all protocols approved by IACUC under protocol number 16-09-3230R. In vivo experiments by using OCI-AML3 and PDX samples were carried out in accordance with the terms of the UK Animals (Scientific Procedures) Act Project License (PPL) (PP4128654).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Plants

Seed stocks	Report on the source of all seed stocks or other plant material used. If applicable, state the seed stock centre and catalogue number. If plant specimens were collected from the field, describe the collection location, date and sampling procedures.
Novel plant genotypes	Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor was applied.
Authentication	Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosaicism, off-target gene editing) were examined.

Flow Cytometry

Plots

Confirm that:

- ☒ The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- ☒ The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- ☒ All plots are contour plots with outliers or pseudocolor plots.
- ☒ A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation	AML sample preparation for flow cytometry based drug sensitivity testing and phosphoflow experiments: Bone marrow (BM) or peripheral blood (PB) samples were collected after informed consent from patients with AML. Mononuclear cells (MNCs) were isolated from BM or PB samples by Ficoll-Paque PREMIUM (GE Healthcare) density gradient separation and viably frozen and stored in liquid nitrogen prior to further analyses. Frozen MNCs were thawed and suspended in 12.5% conditioned medium composed of RPMI 1640 medium (Corning) supplemented with 12.5% HS-5 cell-derived conditioned medium, 10% FBS 2mM L-glutamine and penicillin-streptomycin (100U/ml) then treated with DENARASE (250U/μl, c-Lecta) to degrade DNA released from dead cells, and the cells left to recover for 4 h in 12.5% conditioned medium. The cells were plated onto pre-drugged plates at a density of 50,000 cells/well and incubated with the drugs for 5 days (37°C, 5% CO₂). Flow cytometry: After incubation, the cells were centrifuged (500 x g, 5 minutes) and resuspended in staining buffer (RPMI 1640, 10% FBS 2mM L-glutamine and penicillin-streptomycin (100U/ml)). The cells were stained with antibodies against CD45-FITC (BD Pharmingen), CD34-APC (BD Pharmingen), CD15-PE-Cy7 (Biolegend), CD14-BV421 BD Biosciences), and CD11b-BV605 (BD Horizon) for 30 minutes at room temperature in the dark. Subsequently, the cells were centrifuged (500 x g, 5 minutes) and excess antibodies were removed. The cells were resuspended and stained with PE Annexin V and 7-amino actinomycin D in Annexin V Binding Buffer (BD Pharmingen) for 15 minutes at room temperature in the dark. Phosphoflow: After thawing and DENARASE treatment as described previously, MNCs from AML patient samples were plated onto pre-drugged Nunc™ 96-well V-bottom plate at a density of 200,000 cells/well and incubated with inhibitors for 5 days (37°C, 5% CO₂). After incubation with the drugs, the cells were washed with PBS, centrifuged (1000 x g, 4 minutes) and stained with Zombie Yellow (BioLegend) viability marker for 30 minutes in the dark at room temperature. The cells were washed with staining buffer (5% FBS in DPBs) and stained with surface markers for CD45-BV786 (BD Biosciences), CD38-BV421 (BD Biosciences), CD34-APC-Cy7 (BioLegend) and CD11b-BV605 (BD Horizon) for 30 minutes at room temperature. The cells were fixed in 1.5% paraformaldehyde solution in PBS pre-warmed to 37°C, for 15 minutes at room temperature. Fixed cells were centrifuged (1000 x g for 4 minutes), washed with staining buffer, and centrifuged again with the same settings. The cells were resuspended in ice cold methanol and incubated at 4°C for 30 minutes, after which the cells were washed twice with staining buffer with centrifugation (1000g for 4 minutes). The cells were stained with β-catenin-AF488 (BD Pharmingen) for 1 hour at room temperature. After incubation, the cells were washed with staining buffer, centrifuged (1000g x 4 minutes) and resuspended for analysis.
Instrument	IntelliCyt® iQue Screener PLUS VBR, serial number 3025
Software	ForeCyt® Software v9.0.7822
Cell population abundance	Cells were only analyzed by flow cytometry, no cells were sorted.

Gating strategy

Flow cytometry for AML patient samples: Overall cell population was gated using FSC/SSC. Singlets were gated from overall cell population using FSC-A/FSC-H. Live cells were gated from singlets as Annexin V and 7-AAD negative. AML blasts were gated from CD45+dim and low SSC. CD11b+ blasts were gated from total blast population using SSC and CD11b-BV605. Unstained control was used to set the negative population. Phoshoflow analysis was done similarly, and the β -catenin positive blasts were gated with β -catenin-AF488 from total blast population.

☒ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.